A Study to Investigate the Safety and Pharmacokinetics of a Single Dose of VH3810109 (Also Known as GSK3810109), Administered Either Subcutaneously (SC) With rHuPH20 or Intravenously (IV), in Healthy Adult Participants

A Phase 1, Open-Label, Single-Dose Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, GSK3810109, Administered Either Subcutaneously or Intravenously With Recombinant Human Hyaluronidase PH20 (rHuPH20) to Healthy Adults

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05291520

Acronym

SPAN

Enrollment

Registered

2022-03-22

Start date

2022-02-23

Completion date

2023-04-10

Last updated

2024-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV Infections

Keywords

VH3810109, GSK3810109, HIV, Human Monoclonal Antibody, rHuPH20, Pharmacokinetics, Safety, Tolerability, N6LS

Brief summary

An open-label, two part study to assess the safety, tolerability, and PK of VH3810109 in healthy adult participants. Participants will receive a single SC or IV dose of VH3810109 co-administered with rHuPH20 and will be followed up for 24 weeks.

Interventions

BIOLOGICALVH3810109

VH3810109 was administered.

BIOLOGICALrHuPH20

rHuPH20 was administered.

Study design

Allocation

NON_RANDOMIZED

Intervention model

SEQUENTIAL

Primary purpose

TREATMENT

Masking

NONE

Masking description

This will be an open-label study. Hence, there will be no masking.

Intervention model description

Participants will receive a single SC or IV dose of VH3810109 co-administered with rHuPH20

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

* Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and without history of any of the conditions listed in the

Exclusion criteria

. * Participants having body weight of ≥50 kilogram (kg) and \<100 kg * Participants having a clinical laboratory profile within the normal range or must have results that do not show clinically significant abnormalities, as judged by the investigator at screening. * Contraceptive use by men or women participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Participants who are female at birth are eligible to participate if at least one of the following conditions applies: Not pregnant or breastfeeding and at least one of the following conditions applies: Is not a participant of childbearing potential (POCBP) or Is a POCBP and agree to use an acceptable contraceptive method as described in Section 10.4 from 3 weeks prior to the start of this study and during the study. The investigator should evaluate the effectiveness of the contraceptive method in relationship to the first dose of study intervention. A POCBP must have a negative highly sensitive serum pregnancy test on Day -1, prior to the first dose of study intervention All participants in the study should be counseled on safer sexual practices including the use and benefit/risk of effective barrier methods (e.g., male condom). The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a POCBP with an early undetected pregnancy. * Capable of giving written informed consent.

Design outcomes

Primary

Measure	Time frame	Description
Number of Participants With Grade 2 or Higher (>=) Adverse Events (AEs) Following SC Administration of VH3810109 (Part 1 and Part 3)	Up to Week 24	An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. The Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric AE was used for all AE severity grading, where Grade 1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening. This outcome measure is presenting only data for Grade 2 or more of severity.
Number of Participants With Serious Adverse Events (SAEs) Following SC Administration of VH3810109 (Part 1 and Part 3)	Up to Week 24	An SAE is defined as any untoward medical occurrence that; results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect or other situations as judged by physician.
Number of Participants With Injection Site Reactions (ISRs) Following VH3810109 SC Administration (Part 1 and 3)	Up to 7 days post-dose	ISRs were recorded via ISR diaries and managed through investigator assessment. The participants who experienced any injection site reaction were reported.
Number of Participants With Grade 2 to 4 Elevated Alanin Aminotransferase/Aspartate Aminotransferase (ALT/AST) Values Following VH3810109 SC Administration (Part 1 and 3)	Up to Week 24	Liver chemistry stopping and increased monitoring criteria is analyzed using DAIDS AE Grading Table, where Grade 2 (moderate): causing greater than minimal interference with usual social and functional activities, Grade 3 (severe): causing inability to perform usual social and functional activities, Grade 4 (Potentially life threatening): causing inability to perform basic self-care functions or hospitalization indicated.
Number of Participants With >= Grade 2 AEs Following IV Administration of VH3810109 (Part 2)	Up to Week 24	An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. The Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric AE was used for all AE severity grading, where Grade 1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening. This outcome measure is presenting only data for Grade 2 or more of severity.
Number of Participants With SAEs Following IV Administration of VH3810109 (Part 2)	Up to Week 24	An SAE is defined as any untoward medical occurrence that; results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect or other situations as judged by physician.
Number of Participants With Grade 2 to 4 Elevated ALT/AST Values Following VH3810109 IV Administration (Part 2)	Up to Week 24	Liver chemistry stopping and increased monitoring criteria is analyzed using DAIDS AE Grading Table, where Grade 2 (moderate): causing greater than minimal interference with usual social and functional activities, Grade 3 (severe): causing inability to perform usual social and functional activities, Grade 4 (Potentially life threatening): causing inability to perform basic self-care functions or hospitalization indicated.

Secondary

Measure	Time frame	Description
Number of Participants Reporting Pain, Using Perception of Injection (PIN) Questionnaire (Part 1 and 3)	At Day 2 and Day 7	The PIN questionnaire measure contains 21 items: pain at injection site, local site reactions, impact on functioning and willingness to pursue injectable treatment outside clinical trial. Scores range from 1 to 5; the scores are defined as following: 1=not at all bothered, 2=a little bothered, 3=moderately bothered, 4=very bothered, 5=extremely bothered; questions are phrased to ensure that 1: most favorable perception of vaccination, and 5: most unfavorable. Score of a dimension is calculated as mean of all items with dimension. Higher scores represent worse perception of injection.
Number of Participants Reporting Being Bothered or Affected by the Pain and Local Reactions Based on the PIN Questionaire (Part 1 and 3)	At Day 2 and Day 7	The PIN questionnaire measure contains 21 items: pain at injection site, local site reactions, impact on functioning and willingness to pursue injectable treatment outside clinical trial. Scores range from 1 to 5; the scores are defind as following: 1=totaly acceptable, 2=very acceptable, 3=moderately acceptable, 4=a little acceptable, 5=not at all acceptable; questions are phrased to ensure that 1: most favorable perception of vaccination, and 5: most unfavorable. Score of a dimension is calculated as mean of all items with dimension. Higher scores represent worse perception of injection.
Score Reported for Post-injection Pain Assessment Using Numeric Rating Scale (NRS) Following VH3810109 SC Administration (Part 1 and 3)	At Day 1, Day 2 and Day 7	Post-injection assessment of pain was measured based on NRS which is a 11-point numerical rating scale ranging from 0 (no pain) to 10 (worst possible pain).
Scores Reported for Post-injection Pain Assessment Using Numeric Rating Scale (NRS) Following VH3810109 IV Administration (Part 2)	At Day 1, Day 2 and Day 7	Post-injection assessment of pain was measured based on NRS which is a 11-point numerical rating scale ranging from 0 (no pain) to 10 (worst possible pain).
Number of ISRs Events Overall and by Grade (Part 1 and 3)	Up to day 14	ISRs were recorded via ISR diaries and managed through investigator assessment. Severity of injection site reactions was analyzed using DAIDS AE Grading Table. The severity was categorized into grades as following: Grade 1 (mild): causing no or minimal interference with usual social and functional activities, Grade 2 (moderate): causing greater than minimal interference with usual social and functional activities, Grade 3 (severe): causing inability to perform usual social and functional activities, Grade 4 (Potentially life threatening): causing inability to perform basic self-care functions or hospitalization indicated, Grade 5 (death). Higher grade indicates more severe condition.
The Overall Duration of ISRs, Expressed in Days	From Day 1 up to Day 14	ISRs will be recorded via ISR diaries and managed through investigator assessment.
Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	From Baseline (Day -1) up to Week 24	Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of VH3810109.
Change From Baseline in Hematocrit	From Baseline (Day -1) up to Week 24	Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of VH3810109.
Change From Baseline in Hemoglobin, Albumin and Total Protein	From Baseline (Day -1) up to Week 24	Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of VH3810109.
Change From Baseline in Red Blood Cell Count (RBC)	From Baseline (Day -1) up to Week 24	Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of VH3810109.
Area Under the Plasma Concentration-time Curve (AUC) From Time Zero Extrapolated to Infinity (AUC[0-inf]) of VH3810109	Up to Week 24	Blood samples were collected as assessed by protocol, at specific time points for pharmacokinetic (PK) analysis of VH3810109.
Change From Baseline in Mean Corpuscle Hemoglobin (MCH)	From Baseline (Day -1) up to Week 24	Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of VH3810109.
Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	From Baseline (Day -1) up to Week 24	Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of VH3810109.
Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	From Baseline (Day -1) up to Week 24	Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of VH3810109.
Number of Participants With Worst Case Urinalysis at Post-baseline Compared With Baseline	Day 14 compared with baseline (Day -1)	Urine samples were collected as assessed by protocol, at specific time points for laboratory analysis of VH3810109. At baseline and post-baseline, worst case urinalysis data was determined by comparing the resulted values of the urinalysis for each participant to the normal rage. This endpoint evaluates the changes from baseline for the worst case urinalysis.
Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	From Baseline (Day -1) up to Week 24	ECG values were collected as assessed by protocol, at the indicated time points.
Change From Baseline in Temperature	From Baseline (Day -1) up to Week 24	Temperature was measured at the indicated time points, in a supine position after the participant has been at rest for at least 5 minutes in a quiet setting without distractions.
Change From Baseline in Pulse Rate	From Baseline (Day -1) up to Week 24	Pulse rate was measured at the indicated time points, in a supine position after the participant has been at rest for at least 5 minutes in a quiet setting without distractions.
Change From Baseline in Respiratory Rate	From Baseline (Day -1) up to Week 24	Respiratory rate was measured at the indicated time points, in a supine position after the participant has been at rest for at least 5 minutes in a quiet setting without distractions.
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	From Baseline (Day -1) up to Week 24	Blood pressure was measured at the indicated time points, in a supine position after the participant has been at rest for at least 5 minutes in a quiet setting without distractions.
Change From Baseline in Mean Corpuscle Volume (MCV)	From Baseline (Day -1) up to Week 24	Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of VH3810109.
AUC From Time Zero to Time t (AUC[0-t]) of VH3810109	Up to Week 24	Blood samples were collected as assessed by protocol, at specific time points for PK analysis of VH3810109.
Maximum Observed Concentration (Cmax) of VH3810109	Up to Week 24	Blood samples were collected as assessed by protocol, at specific time points for PK analysis of VH3810109.
Time of Maximum Observed Concentration (Tmax) of VH3810109	Up to Week 24	Blood samples were collected as assessed by protocol, at specific time points for PK analysis of VH3810109.
Apparent Terminal Phase Half-life (t1/2) of VH3810109	Up to Week 24	Blood samples were collected as assessed by protocol, at specific time points for PK analysis of VH3810109.
Score Recorded for Acceptance of ISRs, Using Perception of Injection (PIN) Questionnaire (Part 1 and 3)	At Day 2 and Day 7	The PIN questionnaire measure contains 21 items: pain at injection site, local site reactions, impact on functioning and willingness to pursue injectable treatment outside clinical trial. Scores range from 1 to 5; questions are phrased to ensure that 1: most favorable perception of vaccination, and 5: most unfavorable. Score of a dimension is calculated as mean of all items with dimension. Higher scores represent worse perception of injection.
Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)	From Baseline (Day -1) up to Week 24	Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of VH3810109.

Countries

United States

Participant flow

Participants by arm

Arm	Count
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC] Participants in this group received a single subcutaneous (SC) dose of VH3810109 20 mg/kg co-administered with rHuPH20 at Day 1 and were followed up to 24 weeks.	8
Part 2 Group: VH3810109 60 mg/kg [IV] Participants in this group received a single intravenous (IV) dose of VH3810109 60 mg/kg at Day 1 and were followed up to 24 weeks.	8
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC] Participants in this group received a single subcutaneous (SC) dose of VH3810109 3000 mg co-administered with rHuPH20 at Day 1 and were followed up to 24 weeks.	8
Total	24

Withdrawals & dropouts

Period	Reason	FG000	FG001	FG002
Overall Study	Lost to Follow-up	0	0	1

Baseline characteristics

Characteristic	Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Part 2 Group: VH3810109 60 mg/kg [IV]	Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Total
Age, Continuous	42.8 Years STANDARD_DEVIATION 7.76	40.0 Years STANDARD_DEVIATION 14.45	39.9 Years STANDARD_DEVIATION 10.59	40.87 Years STANDARD_DEVIATION 10.85
Race/Ethnicity, Customized Asian	2 Participants	1 Participants	1 Participants	4 Participants
Race/Ethnicity, Customized Black or African American	1 Participants	2 Participants	4 Participants	7 Participants
Race/Ethnicity, Customized Multiple	0 Participants	1 Participants	0 Participants	1 Participants
Race/Ethnicity, Customized White	5 Participants	4 Participants	3 Participants	12 Participants
Sex: Female, Male Female	5 Participants	7 Participants	3 Participants	15 Participants
Sex: Female, Male Male	3 Participants	1 Participants	5 Participants	9 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk	EG002 affected / at risk
deaths Total, all-cause mortality	0 / 8	0 / 8	0 / 8
other Total, other adverse events	8 / 8	1 / 8	8 / 8
serious Total, serious adverse events	0 / 8	0 / 8	0 / 8

Outcome results

Primary

Number of Participants With >= Grade 2 AEs Following IV Administration of VH3810109 (Part 2)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. The Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric AE was used for all AE severity grading, where Grade 1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening. This outcome measure is presenting only data for Grade 2 or more of severity.

Time frame: Up to Week 24

Population: Analysis was performed on the Safety set which included all participants that received at least one dose of the study intervention and had data for the assessed timepoints and analysis.

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Number of Participants With >= Grade 2 AEs Following IV Administration of VH3810109 (Part 2)	0 Participants

Primary

Number of Participants With Grade 2 or Higher (>=) Adverse Events (AEs) Following SC Administration of VH3810109 (Part 1 and Part 3)

Time frame: Up to Week 24

Population: Analysis was performed on the Safety set which included all participants that received at least one dose of the study intervention and had data for the assessed timepoints and analysis.

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Number of Participants With Grade 2 or Higher (>=) Adverse Events (AEs) Following SC Administration of VH3810109 (Part 1 and Part 3)	7 Participants
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Number of Participants With Grade 2 or Higher (>=) Adverse Events (AEs) Following SC Administration of VH3810109 (Part 1 and Part 3)	8 Participants

Primary

Number of Participants With Grade 2 to 4 Elevated Alanin Aminotransferase/Aspartate Aminotransferase (ALT/AST) Values Following VH3810109 SC Administration (Part 1 and 3)

Liver chemistry stopping and increased monitoring criteria is analyzed using DAIDS AE Grading Table, where Grade 2 (moderate): causing greater than minimal interference with usual social and functional activities, Grade 3 (severe): causing inability to perform usual social and functional activities, Grade 4 (Potentially life threatening): causing inability to perform basic self-care functions or hospitalization indicated.

Time frame: Up to Week 24

Population: Analysis was performed on the Safety set which included all participants that received at least one dose of the study intervention and had data for the assessed timepoints and analysis.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Number of Participants With Grade 2 to 4 Elevated Alanin Aminotransferase/Aspartate Aminotransferase (ALT/AST) Values Following VH3810109 SC Administration (Part 1 and 3)	ALT, Grade 3	0 Participants
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Number of Participants With Grade 2 to 4 Elevated Alanin Aminotransferase/Aspartate Aminotransferase (ALT/AST) Values Following VH3810109 SC Administration (Part 1 and 3)	AST, Grade 2	0 Participants
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Number of Participants With Grade 2 to 4 Elevated Alanin Aminotransferase/Aspartate Aminotransferase (ALT/AST) Values Following VH3810109 SC Administration (Part 1 and 3)	ALT, Grade 4	0 Participants
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Number of Participants With Grade 2 to 4 Elevated Alanin Aminotransferase/Aspartate Aminotransferase (ALT/AST) Values Following VH3810109 SC Administration (Part 1 and 3)	ALT, Grade 2	0 Participants
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Number of Participants With Grade 2 to 4 Elevated Alanin Aminotransferase/Aspartate Aminotransferase (ALT/AST) Values Following VH3810109 SC Administration (Part 1 and 3)	AST, Grade 3	0 Participants
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Number of Participants With Grade 2 to 4 Elevated Alanin Aminotransferase/Aspartate Aminotransferase (ALT/AST) Values Following VH3810109 SC Administration (Part 1 and 3)	AST, Grade 4	0 Participants
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Number of Participants With Grade 2 to 4 Elevated Alanin Aminotransferase/Aspartate Aminotransferase (ALT/AST) Values Following VH3810109 SC Administration (Part 1 and 3)	AST, Grade 3	0 Participants
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Number of Participants With Grade 2 to 4 Elevated Alanin Aminotransferase/Aspartate Aminotransferase (ALT/AST) Values Following VH3810109 SC Administration (Part 1 and 3)	AST, Grade 4	0 Participants
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Number of Participants With Grade 2 to 4 Elevated Alanin Aminotransferase/Aspartate Aminotransferase (ALT/AST) Values Following VH3810109 SC Administration (Part 1 and 3)	ALT, Grade 2	0 Participants
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Number of Participants With Grade 2 to 4 Elevated Alanin Aminotransferase/Aspartate Aminotransferase (ALT/AST) Values Following VH3810109 SC Administration (Part 1 and 3)	ALT, Grade 3	0 Participants
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Number of Participants With Grade 2 to 4 Elevated Alanin Aminotransferase/Aspartate Aminotransferase (ALT/AST) Values Following VH3810109 SC Administration (Part 1 and 3)	AST, Grade 2	0 Participants
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Number of Participants With Grade 2 to 4 Elevated Alanin Aminotransferase/Aspartate Aminotransferase (ALT/AST) Values Following VH3810109 SC Administration (Part 1 and 3)	ALT, Grade 4	0 Participants

Primary

Number of Participants With Grade 2 to 4 Elevated ALT/AST Values Following VH3810109 IV Administration (Part 2)

Time frame: Up to Week 24

Population: Analysis was performed on the Safety set which included all participants that received at least one dose of the study intervention and had data for the assessed timepoints and analysis.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Number of Participants With Grade 2 to 4 Elevated ALT/AST Values Following VH3810109 IV Administration (Part 2)	ALT, Grade 3	0 Participants
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Number of Participants With Grade 2 to 4 Elevated ALT/AST Values Following VH3810109 IV Administration (Part 2)	ALT, Grade 2	0 Participants
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Number of Participants With Grade 2 to 4 Elevated ALT/AST Values Following VH3810109 IV Administration (Part 2)	ALT, Grade 4	0 Participants
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Number of Participants With Grade 2 to 4 Elevated ALT/AST Values Following VH3810109 IV Administration (Part 2)	AST, Grade 2	0 Participants
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Number of Participants With Grade 2 to 4 Elevated ALT/AST Values Following VH3810109 IV Administration (Part 2)	AST, Grade 3	0 Participants
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Number of Participants With Grade 2 to 4 Elevated ALT/AST Values Following VH3810109 IV Administration (Part 2)	AST, Grade 4	0 Participants

Primary

Number of Participants With Injection Site Reactions (ISRs) Following VH3810109 SC Administration (Part 1 and 3)

ISRs were recorded via ISR diaries and managed through investigator assessment. The participants who experienced any injection site reaction were reported.

Time frame: Up to 7 days post-dose

Population: Analysis was performed on the Safety set which included all participants that received at least one dose of the study intervention and had data for the assessed timepoints and analysis.

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Number of Participants With Injection Site Reactions (ISRs) Following VH3810109 SC Administration (Part 1 and 3)	7 Participants
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Number of Participants With Injection Site Reactions (ISRs) Following VH3810109 SC Administration (Part 1 and 3)	8 Participants

Primary

Number of Participants With SAEs Following IV Administration of VH3810109 (Part 2)

An SAE is defined as any untoward medical occurrence that; results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect or other situations as judged by physician.

Time frame: Up to Week 24

Population: Analysis was performed on the Safety set which included all participants that received at least one dose of the study intervention and had data for the assessed timepoints and analysis.

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Number of Participants With SAEs Following IV Administration of VH3810109 (Part 2)	0 Participants

Primary

Number of Participants With Serious Adverse Events (SAEs) Following SC Administration of VH3810109 (Part 1 and Part 3)

Time frame: Up to Week 24

Population: Analysis was performed on the Safety set which included all participants that received at least one dose of the study intervention and had data for the assessed timepoints and analysis.

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Number of Participants With Serious Adverse Events (SAEs) Following SC Administration of VH3810109 (Part 1 and Part 3)	0 Participants
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Number of Participants With Serious Adverse Events (SAEs) Following SC Administration of VH3810109 (Part 1 and Part 3)	0 Participants

Secondary

Apparent Terminal Phase Half-life (t1/2) of VH3810109

Blood samples were collected as assessed by protocol, at specific time points for PK analysis of VH3810109.

Time frame: Up to Week 24

Population: Analysis was performed on PK Parameter Analysis Set, which included participants who received study intervention and for whom valid and evaluable serum PK parameters were derived for the assessed timepoints and analysis.

Arm	Measure	Value (MEAN)
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Apparent Terminal Phase Half-life (t1/2) of VH3810109	38.17 Days
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Apparent Terminal Phase Half-life (t1/2) of VH3810109	46.97 Days
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Apparent Terminal Phase Half-life (t1/2) of VH3810109	44.95 Days

Secondary

Area Under the Plasma Concentration-time Curve (AUC) From Time Zero Extrapolated to Infinity (AUC[0-inf]) of VH3810109

Blood samples were collected as assessed by protocol, at specific time points for pharmacokinetic (PK) analysis of VH3810109.

Time frame: Up to Week 24

Arm	Measure	Value (MEAN)
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Area Under the Plasma Concentration-time Curve (AUC) From Time Zero Extrapolated to Infinity (AUC[0-inf]) of VH3810109	7587 Daymicrogram/mililitre (dayμg/mL)
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Area Under the Plasma Concentration-time Curve (AUC) From Time Zero Extrapolated to Infinity (AUC[0-inf]) of VH3810109	31560 Daymicrogram/mililitre (dayμg/mL)
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Area Under the Plasma Concentration-time Curve (AUC) From Time Zero Extrapolated to Infinity (AUC[0-inf]) of VH3810109	12840 Daymicrogram/mililitre (dayμg/mL)

Secondary

AUC From Time Zero to Time t (AUC[0-t]) of VH3810109

Blood samples were collected as assessed by protocol, at specific time points for PK analysis of VH3810109.

Time frame: Up to Week 24

Arm	Measure	Value (MEAN)
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	AUC From Time Zero to Time t (AUC[0-t]) of VH3810109	6996 day*μg/mL
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	AUC From Time Zero to Time t (AUC[0-t]) of VH3810109	29160 day*μg/mL
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	AUC From Time Zero to Time t (AUC[0-t]) of VH3810109	11590 day*μg/mL

Secondary

Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)

Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of VH3810109.

Time frame: From Baseline (Day -1) up to Week 24

Population: Analysis was performed on PK set, who included participants who received study intervention and for whom valid and evaluable serum PK parameters were derived for the assessed timepoints and analysis.

Arm	Measure	Group	Value (MEAN)	Dispersion
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)	ALT, at Day 14	1.0 International Units per liter (IU/L)	Standard Deviation 1.41
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)	ALP, at Day 2	2.9 International Units per liter (IU/L)	Standard Deviation 3.83
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)	AST, at Week 16	2.9 International Units per liter (IU/L)	Standard Deviation 1.81
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)	ALT, at Week 4	4.3 International Units per liter (IU/L)	Standard Deviation 6.34
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)	ALP, at Week 16	4.8 International Units per liter (IU/L)	Standard Deviation 5.23
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)	AST, at Week 4	3.0 International Units per liter (IU/L)	Standard Deviation 3.51
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)	ALT, at Week 16	4.4 International Units per liter (IU/L)	Standard Deviation 2.72
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)	ALT, at Baseline	11.8 International Units per liter (IU/L)	Standard Deviation 2.71
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)	AST, at Day 14	1.9 International Units per liter (IU/L)	Standard Deviation 2.03
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)	ALT, at Week 24	2.0 International Units per liter (IU/L)	Standard Deviation 4.44
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)	ALP, at Week 4	0.6 International Units per liter (IU/L)	Standard Deviation 6.5
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)	AST, at Day 7	2.8 International Units per liter (IU/L)	Standard Deviation 2.82
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)	AST, at Baseline	14.5 International Units per liter (IU/L)	Standard Deviation 2.39
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)	ALP, at Day 14	7.6 International Units per liter (IU/L)	Standard Deviation 2.97
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)	AST, at Day 2	0.4 International Units per liter (IU/L)	Standard Deviation 2
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)	ALP, at Day 7	4.6 International Units per liter (IU/L)	Standard Deviation 2.77
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)	ALT, at Day 7	1.5 International Units per liter (IU/L)	Standard Deviation 2.83
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)	ALP, at Week 24	-0.1 International Units per liter (IU/L)	Standard Deviation 5.17
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)	ALP, at Baseline	54.6 International Units per liter (IU/L)	Standard Deviation 8.99
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)	ALT, at Day 2	0.6 International Units per liter (IU/L)	Standard Deviation 1.69
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)	AST, at Week 24	2.0 International Units per liter (IU/L)	Standard Deviation 4.78
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)	ALT, at Day 10	-1.0 International Units per liter (IU/L)	Standard Deviation 1.41
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)	ALP, at Day 2	0.6 International Units per liter (IU/L)	Standard Deviation 4.5
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)	ALP, at Day 10	-1.5 International Units per liter (IU/L)	Standard Deviation 4.95
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)	ALP, at Day 14	4.4 International Units per liter (IU/L)	Standard Deviation 4.17
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)	ALT, at Baseline	12.5 International Units per liter (IU/L)	Standard Deviation 4
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)	ALT, at Day 2	-0.5 International Units per liter (IU/L)	Standard Deviation 1.31
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)	ALT, at Day 3	0.5 International Units per liter (IU/L)	Standard Deviation 1.52
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)	ALT, at Day 4	0.5 International Units per liter (IU/L)	Standard Deviation 2.43
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)	ALT, at Day 7	0.5 International Units per liter (IU/L)	Standard Deviation 2.73
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)	ALT, at Day 8	0.8 International Units per liter (IU/L)	Standard Deviation 3.76
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)	ALT, at Day 14	0.6 International Units per liter (IU/L)	Standard Deviation 2.13
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)	ALT, at Week 4	1.6 International Units per liter (IU/L)	Standard Deviation 3.66
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)	ALT, at Week 16	1.4 International Units per liter (IU/L)	Standard Deviation 2.45
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)	ALT, at Week 24	1.3 International Units per liter (IU/L)	Standard Deviation 5.7
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)	AST, at Baseline	16.0 International Units per liter (IU/L)	Standard Deviation 2.98
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)	AST, at Day 2	1.4 International Units per liter (IU/L)	Standard Deviation 1.77
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)	AST, at Day 3	2.7 International Units per liter (IU/L)	Standard Deviation 1.63
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)	AST, at Day 4	1.8 International Units per liter (IU/L)	Standard Deviation 1.72
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)	AST, at Day 7	0.8 International Units per liter (IU/L)	Standard Deviation 3.06
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)	AST, at Day 8	1.0 International Units per liter (IU/L)	Standard Deviation 3.03
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)	AST, at Day 10	-2.5 International Units per liter (IU/L)	Standard Deviation 0.71
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)	AST, at Day 14	1.8 International Units per liter (IU/L)	Standard Deviation 2.76
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)	AST, at Week 4	4.3 International Units per liter (IU/L)	Standard Deviation 8.96
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)	AST, at Week 16	1.1 International Units per liter (IU/L)	Standard Deviation 3.14
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)	AST, at Week 24	0.1 International Units per liter (IU/L)	Standard Deviation 2.47
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)	ALP, at Baseline	55.9 International Units per liter (IU/L)	Standard Deviation 20
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)	ALP, at Day 3	4.7 International Units per liter (IU/L)	Standard Deviation 4.03
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)	ALP, at Day 4	4.0 International Units per liter (IU/L)	Standard Deviation 5.83
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)	ALP, at Day 7	5.9 International Units per liter (IU/L)	Standard Deviation 4.05
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)	ALP, at Day 8	6.8 International Units per liter (IU/L)	Standard Deviation 5.04
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)	ALP, at Week 4	7.9 International Units per liter (IU/L)	Standard Deviation 4.52
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)	ALP, at Week 16	5.4 International Units per liter (IU/L)	Standard Deviation 5.42
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)	ALP, at Week 24	3.3 International Units per liter (IU/L)	Standard Deviation 5.85
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)	ALT, at Day 14	-2.0 International Units per liter (IU/L)	Standard Deviation 5.81
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)	ALP, at Day 14	2.8 International Units per liter (IU/L)	Standard Deviation 4.71
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)	AST, at Week 16	0.4 International Units per liter (IU/L)	Standard Deviation 3.95
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)	ALP, at Baseline	57.1 International Units per liter (IU/L)	Standard Deviation 9.3
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)	ALT, at Day 3	-1.1 International Units per liter (IU/L)	Standard Deviation 4.61
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)	AST, at Week 24	-0.7 International Units per liter (IU/L)	Standard Deviation 2.63
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)	ALT, at Day 7	2.0 International Units per liter (IU/L)	Standard Deviation 7.91
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)	ALT, at Baseline	20.0 International Units per liter (IU/L)	Standard Deviation 8.09
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)	ALP, at Day 2	-2.4 International Units per liter (IU/L)	Standard Deviation 4.44
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)	AST, at Baseline	18.1 International Units per liter (IU/L)	Standard Deviation 2.64
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)	ALP, at Week 4	-1.8 International Units per liter (IU/L)	Standard Deviation 2.76
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)	AST, at Day 2	-1.8 International Units per liter (IU/L)	Standard Deviation 3.06
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)	ALP, at Day 3	0.0 International Units per liter (IU/L)	Standard Deviation 4.81
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)	AST, at Day 3	-0.6 International Units per liter (IU/L)	Standard Deviation 3.42
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)	ALT, at Day 2	-1.8 International Units per liter (IU/L)	Standard Deviation 3.45
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)	AST, at Day 4	0.5 International Units per liter (IU/L)	Standard Deviation 3.66
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)	ALT, at Week 24	-1.3 International Units per liter (IU/L)	Standard Deviation 5.96
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)	ALP, at Day 4	3.0 International Units per liter (IU/L)	Standard Deviation 3.89
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)	AST, at Day 7	2.5 International Units per liter (IU/L)	Standard Deviation 3.74
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)	ALT, at Day 4	-0.8 International Units per liter (IU/L)	Standard Deviation 6.14
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)	ALP, at Week 24	1.6 International Units per liter (IU/L)	Standard Deviation 4.89
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)	ALT, at Week 16	-0.1 International Units per liter (IU/L)	Standard Deviation 7.06
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)	ALP, at Day 7	4.9 International Units per liter (IU/L)	Standard Deviation 5.33
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)	AST, at Day 14	-0.9 International Units per liter (IU/L)	Standard Deviation 3.4
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)	ALT, at Week 4	-1.9 International Units per liter (IU/L)	Standard Deviation 8.18
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)	ALP, at Week 16	1.0 International Units per liter (IU/L)	Standard Deviation 5.39
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)	AST, at Week 4	0.0 International Units per liter (IU/L)	Standard Deviation 4.38

Secondary

Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin

Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of VH3810109.

Time frame: From Baseline (Day -1) up to Week 24

Arm	Measure	Group	Value (MEAN)	Dispersion
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Glucose, at Baseline	5.009778 milligram per deciliter (mg/dL)	Standard Deviation 0.2649736
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Glucose, at Day 2	-0.006939 milligram per deciliter (mg/dL)	Standard Deviation 0.2306696
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Glucose, at Day 7	0.180408 milligram per deciliter (mg/dL)	Standard Deviation 0.1723749
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Glucose, at Day 14	-0.027755 milligram per deciliter (mg/dL)	Standard Deviation 0.2586688
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Glucose, at Week 4	0.027755 milligram per deciliter (mg/dL)	Standard Deviation 0.3857275
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Glucose, at Week 16	-0.180408 milligram per deciliter (mg/dL)	Standard Deviation 0.2254827
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Blood urea nitrogen, at Day 14	0.02678 milligram per deciliter (mg/dL)	Standard Deviation 0.714446
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Blood urea nitrogen, at Week 4	0.31684 milligram per deciliter (mg/dL)	Standard Deviation 0.895135
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Creatinine, at Baseline	68.2890 milligram per deciliter (mg/dL)	Standard Deviation 15.18504
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Creatinine, at Day 2	1.4365 milligram per deciliter (mg/dL)	Standard Deviation 8.05969
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Creatinine, at Day 7	0.0000 milligram per deciliter (mg/dL)	Standard Deviation 5.84472
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Creatinine, at Day 14	0.1105 milligram per deciliter (mg/dL)	Standard Deviation 3.82236
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Creatinine, at Week 16	-0.3315 milligram per deciliter (mg/dL)	Standard Deviation 6.87895
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Creatinine, at Week 24	2.0995 milligram per deciliter (mg/dL)	Standard Deviation 4.25102
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Direct Bilirubin, at Baseline	2.0306 milligram per deciliter (mg/dL)	Standard Deviation 0.49592
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Direct Bilirubin, at Day 2	-0.5771 milligram per deciliter (mg/dL)	Standard Deviation 0.42811
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Direct Bilirubin, at Day 14	-0.2351 milligram per deciliter (mg/dL)	Standard Deviation 0.57763
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Direct Bilirubin, at Week 4	-0.5344 milligram per deciliter (mg/dL)	Standard Deviation 0.62287
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Direct Bilirubin, at Week 16	-0.3206 milligram per deciliter (mg/dL)	Standard Deviation 0.59544
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Direct Bilirubin, at Week 24	-0.3420 milligram per deciliter (mg/dL)	Standard Deviation 0.49222
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Total bilirubin, at Baseline	9.7684 milligram per deciliter (mg/dL)	Standard Deviation 3.95623
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Total bilirubin, at Day 2	-1.9879 milligram per deciliter (mg/dL)	Standard Deviation 2.22382
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Total bilirubin, at Day 14	0.6199 milligram per deciliter (mg/dL)	Standard Deviation 3.02728
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Total bilirubin, at Week 4	-1.7528 milligram per deciliter (mg/dL)	Standard Deviation 3.77392
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Glucose, at Week 24	-0.249795 milligram per deciliter (mg/dL)	Standard Deviation 0.3040408
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Blood urea nitrogen, at Baseline	3.83775 milligram per deciliter (mg/dL)	Standard Deviation 0.731134
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Blood urea nitrogen, at Day 2	1.21380 milligram per deciliter (mg/dL)	Standard Deviation 0.678703
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Blood urea nitrogen, at Day 7	0.30345 milligram per deciliter (mg/dL)	Standard Deviation 1.042747
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Blood urea nitrogen, at Week 16	0.21420 milligram per deciliter (mg/dL)	Standard Deviation 1.260309
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Blood urea nitrogen, at Week 24	0.32576 milligram per deciliter (mg/dL)	Standard Deviation 1.074638
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Creatinine, at Week 4	2.9835 milligram per deciliter (mg/dL)	Standard Deviation 7.05521
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Direct Bilirubin, at Day 7	0.0000 milligram per deciliter (mg/dL)	Standard Deviation 0.43836
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Total bilirubin, at Day 7	1.6031 milligram per deciliter (mg/dL)	Standard Deviation 2.82603
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Total bilirubin, at Week 16	-0.4061 milligram per deciliter (mg/dL)	Standard Deviation 3.45758
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Total bilirubin, at Week 24	0.0428 milligram per deciliter (mg/dL)	Standard Deviation 2.98813
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Total bilirubin, at Day 4	0.0570 milligram per deciliter (mg/dL)	Standard Deviation 2.84018
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Blood urea nitrogen, at Day 7	0.58459 milligram per deciliter (mg/dL)	Standard Deviation 1.250583
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Creatinine, at Week 24	-0.2210 milligram per deciliter (mg/dL)	Standard Deviation 5.62574
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Total bilirubin, at Day 7	-0.2565 milligram per deciliter (mg/dL)	Standard Deviation 3.16102
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Direct Bilirubin, at Baseline	1.7741 milligram per deciliter (mg/dL)	Standard Deviation 0.62621
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Blood urea nitrogen, at Week 16	-0.41948 milligram per deciliter (mg/dL)	Standard Deviation 0.805711
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Direct Bilirubin, at Day 2	-0.2138 milligram per deciliter (mg/dL)	Standard Deviation 0.45473
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Direct Bilirubin, at Day 3	-0.1425 milligram per deciliter (mg/dL)	Standard Deviation 0.45134
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Direct Bilirubin, at Day 4	0.0285 milligram per deciliter (mg/dL)	Standard Deviation 0.47656
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Direct Bilirubin, at Day 7	0.0214 milligram per deciliter (mg/dL)	Standard Deviation 0.4232
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Direct Bilirubin, at Day 8	0.1995 milligram per deciliter (mg/dL)	Standard Deviation 0.5344
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Direct Bilirubin, at Day 10	-0.5130 milligram per deciliter (mg/dL)	Standard Deviation 0.48366
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Direct Bilirubin, at Day 14	-0.3634 milligram per deciliter (mg/dL)	Standard Deviation 0.46997
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Direct Bilirubin, at Week 4	0.0000 milligram per deciliter (mg/dL)	Standard Deviation 0.42872
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Creatinine, at Day 14	0.6630 milligram per deciliter (mg/dL)	Standard Deviation 6.49175
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Direct Bilirubin, at Week 16	-0.2138 milligram per deciliter (mg/dL)	Standard Deviation 0.52308
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Direct Bilirubin, at Week 24	-0.2565 milligram per deciliter (mg/dL)	Standard Deviation 0.61993
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Total bilirubin, at Day 8	0.9405 milligram per deciliter (mg/dL)	Standard Deviation 3.54057
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Total bilirubin, at Baseline	10.4738 milligram per deciliter (mg/dL)	Standard Deviation 3.28512
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Total bilirubin, at Day 2	-1.1115 milligram per deciliter (mg/dL)	Standard Deviation 3.08613
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Total bilirubin, at Day 10	-2.3085 milligram per deciliter (mg/dL)	Standard Deviation 1.81373
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Total bilirubin, at Day 14	-2.4368 milligram per deciliter (mg/dL)	Standard Deviation 2.07377
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Total bilirubin, at Day 3	-0.8550 milligram per deciliter (mg/dL)	Standard Deviation 2.99128
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Total bilirubin, at Week 4	-1.1115 milligram per deciliter (mg/dL)	Standard Deviation 1.51851
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Total bilirubin, at Week 24	-0.6840 milligram per deciliter (mg/dL)	Standard Deviation 3.10368
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Glucose, at Day 14	0.048571 milligram per deciliter (mg/dL)	Standard Deviation 0.3884992
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Glucose, at Week 16	0.076326 milligram per deciliter (mg/dL)	Standard Deviation 0.2138345
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Glucose, at Week 24	-0.208163 milligram per deciliter (mg/dL)	Standard Deviation 0.3557469
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Glucose, at Baseline	5.037533 milligram per deciliter (mg/dL)	Standard Deviation 0.258243
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Glucose, at Day 2	0.256734 milligram per deciliter (mg/dL)	Standard Deviation 0.5881647
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Glucose, at Day 3	-0.018503 milligram per deciliter (mg/dL)	Standard Deviation 0.2930311
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Glucose, at Day 4	-0.027755 milligram per deciliter (mg/dL)	Standard Deviation 0.2868315
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Creatinine, at Day 2	-3.2045 milligram per deciliter (mg/dL)	Standard Deviation 3.97975
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Glucose, at Day 7	0.548161 milligram per deciliter (mg/dL)	Standard Deviation 1.1531574
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Glucose, at Day 8	-0.111020 milligram per deciliter (mg/dL)	Standard Deviation 0.33306
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Glucose, at Day 10	0.000000 milligram per deciliter (mg/dL)	Standard Deviation 0.157006
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Blood urea nitrogen, at Baseline	4.19475 milligram per deciliter (mg/dL)	Standard Deviation 1.376981
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Glucose, at Week 4	-0.124898 milligram per deciliter (mg/dL)	Standard Deviation 0.2842106
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Blood urea nitrogen, at Day 8	0.55930 milligram per deciliter (mg/dL)	Standard Deviation 0.8099
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Blood urea nitrogen, at Day 10	0.35700 milligram per deciliter (mg/dL)	Standard Deviation 0
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Blood urea nitrogen, at Day 2	0.39270 milligram per deciliter (mg/dL)	Standard Deviation 0.937762
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Blood urea nitrogen, at Day 14	-0.33915 milligram per deciliter (mg/dL)	Standard Deviation 1.192768
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Blood urea nitrogen, at Week 4	-0.16065 milligram per deciliter (mg/dL)	Standard Deviation 0.695659
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Blood urea nitrogen, at Week 24	0.26775 milligram per deciliter (mg/dL)	Standard Deviation 1.47442
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Blood urea nitrogen, at Day 3	0.67830 milligram per deciliter (mg/dL)	Standard Deviation 0.651268
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Creatinine, at Baseline	68.0680 milligram per deciliter (mg/dL)	Standard Deviation 13.56381
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Creatinine, at Day 3	-0.7367 milligram per deciliter (mg/dL)	Standard Deviation 6.16058
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Creatinine, at Day 4	-0.5893 milligram per deciliter (mg/dL)	Standard Deviation 6.03887
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Blood urea nitrogen, at Day 4	0.82705 milligram per deciliter (mg/dL)	Standard Deviation 0.92749
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Creatinine, at Day 7	2.4310 milligram per deciliter (mg/dL)	Standard Deviation 6.71158
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Creatinine, at Day 8	-0.4420 milligram per deciliter (mg/dL)	Standard Deviation 6.0151
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Creatinine, at Day 10	11.9340 milligram per deciliter (mg/dL)	Standard Deviation 3.12541
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Creatinine, at Week 4	0.1105 milligram per deciliter (mg/dL)	Standard Deviation 4.18485
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Total bilirubin, at Week 16	-1.5390 milligram per deciliter (mg/dL)	Standard Deviation 2.90772
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Creatinine, at Week 16	-0.7735 milligram per deciliter (mg/dL)	Standard Deviation 7.98314
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Creatinine, at Day 2	2.3205 milligram per deciliter (mg/dL)	Standard Deviation 9.02667
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Total bilirubin, at Day 4	2.0306 milligram per deciliter (mg/dL)	Standard Deviation 4.6485
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Creatinine, at Day 3	3.6465 milligram per deciliter (mg/dL)	Standard Deviation 5.49905
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Glucose, at Day 3	0.201224 milligram per deciliter (mg/dL)	Standard Deviation 0.3645321
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Creatinine, at Day 4	0.8840 milligram per deciliter (mg/dL)	Standard Deviation 7.94898
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Total bilirubin, at Baseline	12.5258 milligram per deciliter (mg/dL)	Standard Deviation 7.47987
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Total bilirubin, at Week 16	-2.4917 milligram per deciliter (mg/dL)	Standard Deviation 2.46196
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Creatinine, at Day 7	6.2985 milligram per deciliter (mg/dL)	Standard Deviation 9.30077
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Blood urea nitrogen, at Day 7	-0.42840 milligram per deciliter (mg/dL)	Standard Deviation 1.421995
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Glucose, at Day 4	-0.006939 milligram per deciliter (mg/dL)	Standard Deviation 0.2852734
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Blood urea nitrogen, at Day 4	0.15619 milligram per deciliter (mg/dL)	Standard Deviation 1.726718
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Total bilirubin, at Day 2	0.6413 milligram per deciliter (mg/dL)	Standard Deviation 2.98813
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Creatinine, at Week 4	2.7625 milligram per deciliter (mg/dL)	Standard Deviation 6.78911
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Creatinine, at Baseline	73.8140 milligram per deciliter (mg/dL)	Standard Deviation 15.20157
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Total bilirubin, at Day 14	-0.6199 milligram per deciliter (mg/dL)	Standard Deviation 3.52222
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Creatinine, at Week 16	3.1571 milligram per deciliter (mg/dL)	Standard Deviation 5.32501
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Blood urea nitrogen, at Week 4	-0.24098 milligram per deciliter (mg/dL)	Standard Deviation 1.082288
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Glucose, at Day 7	0.166530 milligram per deciliter (mg/dL)	Standard Deviation 0.3408978
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Creatinine, at Week 24	5.6829 milligram per deciliter (mg/dL)	Standard Deviation 7.60201
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Total bilirubin, at Week 4	-0.3206 milligram per deciliter (mg/dL)	Standard Deviation 3.67145
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Blood urea nitrogen, at Day 3	0.16511 milligram per deciliter (mg/dL)	Standard Deviation 1.369415
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Direct Bilirubin, at Baseline	2.1161 milligram per deciliter (mg/dL)	Standard Deviation 1.04191
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Total bilirubin, at Week 24	-1.6856 milligram per deciliter (mg/dL)	Standard Deviation 2.637
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Blood urea nitrogen, at Week 24	-0.05610 milligram per deciliter (mg/dL)	Standard Deviation 1.187055
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Direct Bilirubin, at Day 2	-0.0214 milligram per deciliter (mg/dL)	Standard Deviation 0.4425
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Glucose, at Day 14	0.006939 milligram per deciliter (mg/dL)	Standard Deviation 0.2790329
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Direct Bilirubin, at Day 3	-0.1069 milligram per deciliter (mg/dL)	Standard Deviation 0.43776
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Blood urea nitrogen, at Day 14	-0.50873 milligram per deciliter (mg/dL)	Standard Deviation 1.656633
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Direct Bilirubin, at Day 4	0.1283 milligram per deciliter (mg/dL)	Standard Deviation 0.58348
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Glucose, at Week 16	0.111020 milligram per deciliter (mg/dL)	Standard Deviation 0.3376541
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Direct Bilirubin, at Day 7	-0.1283 milligram per deciliter (mg/dL)	Standard Deviation 0.33893
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Total bilirubin, at Day 3	0.4061 milligram per deciliter (mg/dL)	Standard Deviation 3.48526
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Blood urea nitrogen, at Baseline	4.73025 milligram per deciliter (mg/dL)	Standard Deviation 1.594955
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Blood urea nitrogen, at Week 16	0.03060 milligram per deciliter (mg/dL)	Standard Deviation 1.359639
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Blood urea nitrogen, at Day 2	0.27221 milligram per deciliter (mg/dL)	Standard Deviation 1.307383
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Direct Bilirubin, at Day 14	-0.1710 milligram per deciliter (mg/dL)	Standard Deviation 0.44778
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Total bilirubin, at Day 7	-0.4703 milligram per deciliter (mg/dL)	Standard Deviation 2.08181
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Glucose, at Baseline	4.864064 milligram per deciliter (mg/dL)	Standard Deviation 0.2032812
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Direct Bilirubin, at Week 4	-0.1496 milligram per deciliter (mg/dL)	Standard Deviation 0.50427
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Glucose, at Week 24	0.237900 milligram per deciliter (mg/dL)	Standard Deviation 0.3184202
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Glucose, at Week 4	0.215101 milligram per deciliter (mg/dL)	Standard Deviation 0.5168587
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Direct Bilirubin, at Week 16	-0.7817 milligram per deciliter (mg/dL)	Standard Deviation 0.56591
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Creatinine, at Day 14	3.4255 milligram per deciliter (mg/dL)	Standard Deviation 5.9851
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Glucose, at Day 2	0.145714 milligram per deciliter (mg/dL)	Standard Deviation 0.2966207
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin	Direct Bilirubin, at Week 24	-0.3176 milligram per deciliter (mg/dL)	Standard Deviation 0.36178

Secondary

Change From Baseline in Hematocrit

Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of VH3810109.

Time frame: From Baseline (Day -1) up to Week 24

Arm	Measure	Group	Value (MEAN)	Dispersion
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Hematocrit	Day 14	0.0118 Proportion of red blood cells in blood	Standard Deviation 0.01426
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Hematocrit	Day 7	0.0168 Proportion of red blood cells in blood	Standard Deviation 0.01662
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Hematocrit	Baseline	0.3873 Proportion of red blood cells in blood	Standard Deviation 0.04541
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Hematocrit	Week 4	0.0016 Proportion of red blood cells in blood	Standard Deviation 0.01672
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Hematocrit	Week 24	0.0119 Proportion of red blood cells in blood	Standard Deviation 0.01389
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Hematocrit	Week 16	0.0196 Proportion of red blood cells in blood	Standard Deviation 0.02303
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Hematocrit	Day 2	0.0159 Proportion of red blood cells in blood	Standard Deviation 0.02226
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Hematocrit	Day 3	0.0100 Proportion of red blood cells in blood	Standard Deviation 0.02612
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Hematocrit	Day 4	0.0003 Proportion of red blood cells in blood	Standard Deviation 0.01992
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Hematocrit	Day 7	0.0043 Proportion of red blood cells in blood	Standard Deviation 0.01521
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Hematocrit	Day 8	0.0062 Proportion of red blood cells in blood	Standard Deviation 0.01781
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Hematocrit	Day 10	-0.0270 Proportion of red blood cells in blood	Standard Deviation 0.01131
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Hematocrit	Week 4	-0.0013 Proportion of red blood cells in blood	Standard Deviation 0.01641
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Hematocrit	Week 16	0.0078 Proportion of red blood cells in blood	Standard Deviation 0.02315
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Hematocrit	Baseline	0.3928 Proportion of red blood cells in blood	Standard Deviation 0.04415
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Hematocrit	Day 2	0.0005 Proportion of red blood cells in blood	Standard Deviation 0.01513
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Hematocrit	Day 14	-0.0074 Proportion of red blood cells in blood	Standard Deviation 0.01736
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Hematocrit	Week 24	0.0053 Proportion of red blood cells in blood	Standard Deviation 0.02437
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Hematocrit	Day 7	-0.0065 Proportion of red blood cells in blood	Standard Deviation 0.01208
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Hematocrit	Day 3	0.0066 Proportion of red blood cells in blood	Standard Deviation 0.01502
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Hematocrit	Day 2	0.0118 Proportion of red blood cells in blood	Standard Deviation 0.01704
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Hematocrit	Day 4	0.0023 Proportion of red blood cells in blood	Standard Deviation 0.01646
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Hematocrit	Week 4	-0.0069 Proportion of red blood cells in blood	Standard Deviation 0.01605
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Hematocrit	Week 24	-0.0076 Proportion of red blood cells in blood	Standard Deviation 0.03243
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Hematocrit	Day 14	-0.0056 Proportion of red blood cells in blood	Standard Deviation 0.0142
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Hematocrit	Week 16	-0.0106 Proportion of red blood cells in blood	Standard Deviation 0.00759
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Hematocrit	Baseline	0.4253 Proportion of red blood cells in blood	Standard Deviation 0.04709

Secondary

Change From Baseline in Hemoglobin, Albumin and Total Protein

Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of VH3810109.

Time frame: From Baseline (Day -1) up to Week 24

Arm	Measure	Group	Value (MEAN)	Dispersion
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Hemoglobin, Albumin and Total Protein	Albumin, at Day 2	0.4 Grams per liter (g/L)	Standard Deviation 2.07
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Hemoglobin, Albumin and Total Protein	Albumin, at Week 16	0.6 Grams per liter (g/L)	Standard Deviation 1.77
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Hemoglobin, Albumin and Total Protein	Hemoglobin, at Week 16	4.3 Grams per liter (g/L)	Standard Deviation 7.23
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Hemoglobin, Albumin and Total Protein	Hemoglobin, at Day 2	5.8 Grams per liter (g/L)	Standard Deviation 6.9
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Hemoglobin, Albumin and Total Protein	Hemoglobin, at Baseline	131.4 Grams per liter (g/L)	Standard Deviation 16.78
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Hemoglobin, Albumin and Total Protein	Total Protein, at Day 14	0.0 Grams per liter (g/L)	Standard Deviation 4.14
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Hemoglobin, Albumin and Total Protein	Hemoglobin, at Day 14	3.4 Grams per liter (g/L)	Standard Deviation 4.78
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Hemoglobin, Albumin and Total Protein	Total Protein, at Week 24	-3.4 Grams per liter (g/L)	Standard Deviation 3.96
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Hemoglobin, Albumin and Total Protein	Albumin, at Day 7	0.1 Grams per liter (g/L)	Standard Deviation 2.8
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Hemoglobin, Albumin and Total Protein	Albumin, at Week 24	-1.5 Grams per liter (g/L)	Standard Deviation 2.14
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Hemoglobin, Albumin and Total Protein	Total Protein, at Week 16	0.9 Grams per liter (g/L)	Standard Deviation 2.42
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Hemoglobin, Albumin and Total Protein	Albumin, at Week 4	-1.4 Grams per liter (g/L)	Standard Deviation 2.56
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Hemoglobin, Albumin and Total Protein	Hemoglobin, at Week 4	1.0 Grams per liter (g/L)	Standard Deviation 5.29
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Hemoglobin, Albumin and Total Protein	Total Protein, at Week 4	-0.6 Grams per liter (g/L)	Standard Deviation 3.16
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Hemoglobin, Albumin and Total Protein	Total Protein, at Day 2	0.6 Grams per liter (g/L)	Standard Deviation 4.17
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Hemoglobin, Albumin and Total Protein	Total Protein, at Day 7	0.0 Grams per liter (g/L)	Standard Deviation 4.57
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Hemoglobin, Albumin and Total Protein	Hemoglobin, at Day 7	2.6 Grams per liter (g/L)	Standard Deviation 6.35
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Hemoglobin, Albumin and Total Protein	Albumin, at Day 14	0.0 Grams per liter (g/L)	Standard Deviation 2
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Hemoglobin, Albumin and Total Protein	Hemoglobin, at Week 24	0.4 Grams per liter (g/L)	Standard Deviation 4.07
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Hemoglobin, Albumin and Total Protein	Total Protein, at Baseline	70.0 Grams per liter (g/L)	Standard Deviation 3.85
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Hemoglobin, Albumin and Total Protein	Albumin, at Baseline	44.0 Grams per liter (g/L)	Standard Deviation 3.02
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Hemoglobin, Albumin and Total Protein	Hemoglobin, at Day 8	3.3 Grams per liter (g/L)	Standard Deviation 4.84
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Hemoglobin, Albumin and Total Protein	Hemoglobin, at Day 2	1.9 Grams per liter (g/L)	Standard Deviation 4.61
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Hemoglobin, Albumin and Total Protein	Hemoglobin, at Day 3	6.8 Grams per liter (g/L)	Standard Deviation 6.79
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Hemoglobin, Albumin and Total Protein	Hemoglobin, at Day 4	4.8 Grams per liter (g/L)	Standard Deviation 7.19
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Hemoglobin, Albumin and Total Protein	Hemoglobin, at Day 7	2.9 Grams per liter (g/L)	Standard Deviation 5.28
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Hemoglobin, Albumin and Total Protein	Hemoglobin, at Day 10	-10.0 Grams per liter (g/L)	Standard Deviation 4.24
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Hemoglobin, Albumin and Total Protein	Hemoglobin, at Day 14	-0.8 Grams per liter (g/L)	Standard Deviation 5.9
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Hemoglobin, Albumin and Total Protein	Hemoglobin, at Week 16	5.3 Grams per liter (g/L)	Standard Deviation 8.01
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Hemoglobin, Albumin and Total Protein	Hemoglobin, at Week 24	4.0 Grams per liter (g/L)	Standard Deviation 7.54
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Hemoglobin, Albumin and Total Protein	Albumin, at Day 2	-2.4 Grams per liter (g/L)	Standard Deviation 2.45
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Hemoglobin, Albumin and Total Protein	Albumin, at Day 3	-0.3 Grams per liter (g/L)	Standard Deviation 1.86
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Hemoglobin, Albumin and Total Protein	Albumin, at Day 4	-0.8 Grams per liter (g/L)	Standard Deviation 2.4
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Hemoglobin, Albumin and Total Protein	Total Protein, at Day 2	-1.4 Grams per liter (g/L)	Standard Deviation 4.17
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Hemoglobin, Albumin and Total Protein	Albumin, at Day 7	-1.9 Grams per liter (g/L)	Standard Deviation 1.81
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Hemoglobin, Albumin and Total Protein	Albumin, at Day 8	-1.7 Grams per liter (g/L)	Standard Deviation 1.75
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Hemoglobin, Albumin and Total Protein	Total Protein, at Baseline	71.0 Grams per liter (g/L)	Standard Deviation 3.66
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Hemoglobin, Albumin and Total Protein	Total Protein, at Day 7	-2.8 Grams per liter (g/L)	Standard Deviation 2.76
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Hemoglobin, Albumin and Total Protein	Total Protein, at Day 8	2.76 Grams per liter (g/L)	Standard Deviation 2.86
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Hemoglobin, Albumin and Total Protein	Total Protein, at Day 10	-8.0 Grams per liter (g/L)	Standard Deviation 0
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Hemoglobin, Albumin and Total Protein	Total Protein, at Week 4	-1.0 Grams per liter (g/L)	Standard Deviation 3.38
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Hemoglobin, Albumin and Total Protein	Total Protein, at Week 16	1.0 Grams per liter (g/L)	Standard Deviation 3.85
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Hemoglobin, Albumin and Total Protein	Total Protein, at Week 24	0.1 Grams per liter (g/L)	Standard Deviation 2.17
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Hemoglobin, Albumin and Total Protein	Hemoglobin, at Baseline	128.3 Grams per liter (g/L)	Standard Deviation 15.83
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Hemoglobin, Albumin and Total Protein	Hemoglobin, at Week 4	0.4 Grams per liter (g/L)	Standard Deviation 6.55
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Hemoglobin, Albumin and Total Protein	Albumin, at Baseline	43.9 Grams per liter (g/L)	Standard Deviation 3
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Hemoglobin, Albumin and Total Protein	Albumin, at Day 10	-5.5 Grams per liter (g/L)	Standard Deviation 0.71
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Hemoglobin, Albumin and Total Protein	Albumin, at Day 14	-1.0 Grams per liter (g/L)	Standard Deviation 1.51
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Hemoglobin, Albumin and Total Protein	Albumin, at Week 4	-0.1 Grams per liter (g/L)	Standard Deviation 2.1
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Hemoglobin, Albumin and Total Protein	Albumin, at Week 16	0.8 Grams per liter (g/L)	Standard Deviation 2.19
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Hemoglobin, Albumin and Total Protein	Albumin, at Week 24	-0.3 Grams per liter (g/L)	Standard Deviation 1.04
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Hemoglobin, Albumin and Total Protein	Total Protein, at Day 3	1.3 Grams per liter (g/L)	Standard Deviation 3.93
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Hemoglobin, Albumin and Total Protein	Total Protein, at Day 4	0.0 Grams per liter (g/L)	Standard Deviation 4.43
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Hemoglobin, Albumin and Total Protein	Total Protein, at Day 14	-1.6 Grams per liter (g/L)	Standard Deviation 2.56
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Hemoglobin, Albumin and Total Protein	Hemoglobin, at Baseline	142.4 Grams per liter (g/L)	Standard Deviation 15.67
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Hemoglobin, Albumin and Total Protein	Hemoglobin, at Day 4	3.9 Grams per liter (g/L)	Standard Deviation 5.46
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Hemoglobin, Albumin and Total Protein	Hemoglobin, at Week 4	-1.4 Grams per liter (g/L)	Standard Deviation 4.96
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Hemoglobin, Albumin and Total Protein	Albumin, at Day 2	-0.3 Grams per liter (g/L)	Standard Deviation 1.83
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Hemoglobin, Albumin and Total Protein	Hemoglobin, at Week 24	-1.4 Grams per liter (g/L)	Standard Deviation 13.99
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Hemoglobin, Albumin and Total Protein	Hemoglobin, at Day 2	3.9 Grams per liter (g/L)	Standard Deviation 6.49
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Hemoglobin, Albumin and Total Protein	Albumin, at Baseline	43.9 Grams per liter (g/L)	Standard Deviation 3.44
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Hemoglobin, Albumin and Total Protein	Albumin, at Week 24	-1.9 Grams per liter (g/L)	Standard Deviation 2.48
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Hemoglobin, Albumin and Total Protein	Hemoglobin, at Week 16	-3.4 Grams per liter (g/L)	Standard Deviation 4.12
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Hemoglobin, Albumin and Total Protein	Hemoglobin, at Day 3	4.3 Grams per liter (g/L)	Standard Deviation 5.39
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Hemoglobin, Albumin and Total Protein	Total Protein, at Day 2	-1.5 Grams per liter (g/L)	Standard Deviation 3.51
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Hemoglobin, Albumin and Total Protein	Albumin, at Day 14	-0.1 Grams per liter (g/L)	Standard Deviation 1.89
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Hemoglobin, Albumin and Total Protein	Total Protein, at Day 7	-0.1 Grams per liter (g/L)	Standard Deviation 3.52
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Hemoglobin, Albumin and Total Protein	Hemoglobin, at Day 14	-0.4 Grams per liter (g/L)	Standard Deviation 4.47
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Hemoglobin, Albumin and Total Protein	Total Protein, at Day 4	0.6 Grams per liter (g/L)	Standard Deviation 2.2
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Hemoglobin, Albumin and Total Protein	Total Protein, at Day 14	-0.8 Grams per liter (g/L)	Standard Deviation 2.71
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Hemoglobin, Albumin and Total Protein	Total Protein, at Baseline	72.3 Grams per liter (g/L)	Standard Deviation 4.4
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Hemoglobin, Albumin and Total Protein	Albumin, at Week 4	-0.3 Grams per liter (g/L)	Standard Deviation 2.43
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Hemoglobin, Albumin and Total Protein	Total Protein, at Week 4	-1.9 Grams per liter (g/L)	Standard Deviation 3.14
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Hemoglobin, Albumin and Total Protein	Albumin, at Day 7	0.4 Grams per liter (g/L)	Standard Deviation 2
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Hemoglobin, Albumin and Total Protein	Hemoglobin, at Day 7	-0.4 Grams per liter (g/L)	Standard Deviation 4.37
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Hemoglobin, Albumin and Total Protein	Total Protein, at Week 16	-4.4 Grams per liter (g/L)	Standard Deviation 3.87
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Hemoglobin, Albumin and Total Protein	Albumin, at Day 4	0.3 Grams per liter (g/L)	Standard Deviation 1.58
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Hemoglobin, Albumin and Total Protein	Total Protein, at Day 3	-1.9 Grams per liter (g/L)	Standard Deviation 3.04
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Hemoglobin, Albumin and Total Protein	Total Protein, at Week 24	-2.7 Grams per liter (g/L)	Standard Deviation 4.46
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Hemoglobin, Albumin and Total Protein	Albumin, at Day 3	-0.1 Grams per liter (g/L)	Standard Deviation 1.73
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Hemoglobin, Albumin and Total Protein	Albumin, at Week 16	-2.0 Grams per liter (g/L)	Standard Deviation 2.16

Secondary

Change From Baseline in Mean Corpuscle Hemoglobin (MCH)

Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of VH3810109.

Time frame: From Baseline (Day -1) up to Week 24

Arm	Measure	Group	Value (MEAN)	Dispersion
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Mean Corpuscle Hemoglobin (MCH)	Baseline	29.05 picograms (pg)	Standard Deviation 1.028
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Mean Corpuscle Hemoglobin (MCH)	Week 4	-0.09 picograms (pg)	Standard Deviation 0.608
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Mean Corpuscle Hemoglobin (MCH)	Day 7	-0.36 picograms (pg)	Standard Deviation 0.302
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Mean Corpuscle Hemoglobin (MCH)	Week 24	-0.39 picograms (pg)	Standard Deviation 1.051
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Mean Corpuscle Hemoglobin (MCH)	Day 14	-0.06 picograms (pg)	Standard Deviation 0.475
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Mean Corpuscle Hemoglobin (MCH)	Day 2	0.20 picograms (pg)	Standard Deviation 0.553
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Mean Corpuscle Hemoglobin (MCH)	Week 16	-0.21 picograms (pg)	Standard Deviation 0.613
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Mean Corpuscle Hemoglobin (MCH)	Day 10	-0.20 picograms (pg)	Standard Deviation 0.141
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Mean Corpuscle Hemoglobin (MCH)	Week 24	0.39 picograms (pg)	Standard Deviation 0.716
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Mean Corpuscle Hemoglobin (MCH)	Baseline	28.33 picograms (pg)	Standard Deviation 2.213
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Mean Corpuscle Hemoglobin (MCH)	Day 2	0.21 picograms (pg)	Standard Deviation 0.458
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Mean Corpuscle Hemoglobin (MCH)	Day 3	0.63 picograms (pg)	Standard Deviation 0.836
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Mean Corpuscle Hemoglobin (MCH)	Day 4	0.67 picograms (pg)	Standard Deviation 0.463
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Mean Corpuscle Hemoglobin (MCH)	Day 7	0.16 picograms (pg)	Standard Deviation 0.385
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Mean Corpuscle Hemoglobin (MCH)	Day 8	0.27 picograms (pg)	Standard Deviation 0.48
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Mean Corpuscle Hemoglobin (MCH)	Day 14	0.44 picograms (pg)	Standard Deviation 0.524
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Mean Corpuscle Hemoglobin (MCH)	Week 4	0.39 picograms (pg)	Standard Deviation 0.617
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Mean Corpuscle Hemoglobin (MCH)	Week 16	0.39 picograms (pg)	Standard Deviation 0.779
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Mean Corpuscle Hemoglobin (MCH)	Day 4	0.55 picograms (pg)	Standard Deviation 0.678
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Mean Corpuscle Hemoglobin (MCH)	Week 24	0.31 picograms (pg)	Standard Deviation 1.524
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Mean Corpuscle Hemoglobin (MCH)	Week 4	0.16 picograms (pg)	Standard Deviation 0.466
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Mean Corpuscle Hemoglobin (MCH)	Day 3	0.39 picograms (pg)	Standard Deviation 0.29
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Mean Corpuscle Hemoglobin (MCH)	Baseline	29.26 picograms (pg)	Standard Deviation 1.66
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Mean Corpuscle Hemoglobin (MCH)	Week 16	0.24 picograms (pg)	Standard Deviation 0.737
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Mean Corpuscle Hemoglobin (MCH)	Day 7	0.29 picograms (pg)	Standard Deviation 0.536
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Mean Corpuscle Hemoglobin (MCH)	Day 2	-0.08 picograms (pg)	Standard Deviation 0.345
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Mean Corpuscle Hemoglobin (MCH)	Day 14	0.33 picograms (pg)	Standard Deviation 0.59

Secondary

Change From Baseline in Mean Corpuscle Volume (MCV)

Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of VH3810109.

Time frame: From Baseline (Day -1) up to Week 24

Arm	Measure	Group	Value (MEAN)	Dispersion
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Mean Corpuscle Volume (MCV)	Baseline	85.78 cubic microns	Standard Deviation 2.013
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Mean Corpuscle Volume (MCV)	Day 2	0.14 cubic microns	Standard Deviation 0.466
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Mean Corpuscle Volume (MCV)	Day 7	0.84 cubic microns	Standard Deviation 0.661
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Mean Corpuscle Volume (MCV)	Day 14	0.06 cubic microns	Standard Deviation 0.784
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Mean Corpuscle Volume (MCV)	Week 4	-0.53 cubic microns	Standard Deviation 1.216
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Mean Corpuscle Volume (MCV)	Week 16	0.76 cubic microns	Standard Deviation 0.842
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Mean Corpuscle Volume (MCV)	Week 24	1.34 cubic microns	Standard Deviation 1.983
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Mean Corpuscle Volume (MCV)	Week 16	-0.75 cubic microns	Standard Deviation 2.522
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Mean Corpuscle Volume (MCV)	Week 4	0.34 cubic microns	Standard Deviation 1.125
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Mean Corpuscle Volume (MCV)	Day 8	-0.27 cubic microns	Standard Deviation 0.674
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Mean Corpuscle Volume (MCV)	Baseline	86.89 cubic microns	Standard Deviation 6.081
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Mean Corpuscle Volume (MCV)	Day 10	0.05 cubic microns	Standard Deviation 0.354
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Mean Corpuscle Volume (MCV)	Week 24	-0.41 cubic microns	Standard Deviation 2.107
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Mean Corpuscle Volume (MCV)	Day 2	-0.66 cubic microns	Standard Deviation 0.478
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Mean Corpuscle Volume (MCV)	Day 7	-0.61 cubic microns	Standard Deviation 0.562
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Mean Corpuscle Volume (MCV)	Day 3	-0.72 cubic microns	Standard Deviation 0.492
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Mean Corpuscle Volume (MCV)	Day 14	0.04 cubic microns	Standard Deviation 0.746
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Mean Corpuscle Volume (MCV)	Day 4	-1.38 cubic microns	Standard Deviation 0.542
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Mean Corpuscle Volume (MCV)	Day 14	0.06 cubic microns	Standard Deviation 0.623
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Mean Corpuscle Volume (MCV)	Day 4	-0.41 cubic microns	Standard Deviation 0.589
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Mean Corpuscle Volume (MCV)	Week 4	-0.03 cubic microns	Standard Deviation 0.703
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Mean Corpuscle Volume (MCV)	Day 7	-0.10 cubic microns	Standard Deviation 0.469
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Mean Corpuscle Volume (MCV)	Week 16	0.74 cubic microns	Standard Deviation 1.078
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Mean Corpuscle Volume (MCV)	Day 3	-0.03 cubic microns	Standard Deviation 0.345
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Mean Corpuscle Volume (MCV)	Week 24	0.40 cubic microns	Standard Deviation 2.195
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Mean Corpuscle Volume (MCV)	Baseline	87.28 cubic microns	Standard Deviation 3.478
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Mean Corpuscle Volume (MCV)	Day 2	-0.03 cubic microns	Standard Deviation 0.354

Secondary

Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils

Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of VH3810109.

Time frame: From Baseline (Day -1) up to Week 24

Arm	Measure	Group	Value (MEAN)	Dispersion
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Neutrophils, at Day 14	-0.340 10^9 cells/L	Standard Deviation 0.7531
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Lymphocytes, at Day 14	-0.019 10^9 cells/L	Standard Deviation 0.1664
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Neutrophils, at Day 2	0.315 10^9 cells/L	Standard Deviation 0.8333
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	WBC, at Day 7	0.11 10^9 cells/L	Standard Deviation 0.872
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Eosinophils, at Day 14	0.059 10^9 cells/L	Standard Deviation 0.0718
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Basophils, at Baseline	0.033 10^9 cells/L	Standard Deviation 0.0139
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Platelets, at Day 7	1.4 10^9 cells/L	Standard Deviation 13.65
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Neutrophils, at Week 4	-0.160 10^9 cells/L	Standard Deviation 1.2887
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	WBC, at Day 14	-0.26 10^9 cells/L	Standard Deviation 0.809
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Monocytes, at Week 4	0.036 10^9 cells/L	Standard Deviation 0.1061
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Monocytes, at Day 2	0.091 10^9 cells/L	Standard Deviation 0.1037
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	WBC, at Week 4	-0.03 10^9 cells/L	Standard Deviation 1.261
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Neutrophils, at Week 16	-0.178 10^9 cells/L	Standard Deviation 0.6481
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Platelets, at Day 14	19.9 10^9 cells/L	Standard Deviation 32.89
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Basophils, at Day 2	-0.004 10^9 cells/L	Standard Deviation 0.0092
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	WBC, at Week 24	-0.46 10^9 cells/L	Standard Deviation 0.883
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Eosinophils, at Day 2	0.018 10^9 cells/L	Standard Deviation 0.0851
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Neutrophils, at Day 7	0.066 10^9 cells/L	Standard Deviation 0.8177
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Lymphocytes, at Baseline	1.368 10^9 cells/L	Standard Deviation 0.268
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Platelets, at Week 4	30.6 10^9 cells/L	Standard Deviation 87.1
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	WBC, at Week 16	0.01 10^9 cells/L	Standard Deviation 0.892
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Lymphocytes, at Day 2	0.006 10^9 cells/L	Standard Deviation 0.1908
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Eosinophils, at Baseline	0.121 10^9 cells/L	Standard Deviation 0.0957
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Platelets, at Week 24	1.1 10^9 cells/L	Standard Deviation 27.58
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Neutrophils, at Week 24	-0.535 10^9 cells/L	Standard Deviation 0.8511
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Monocytes, at Week 24	-0.018 10^9 cells/L	Standard Deviation 0.1099
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Eosinophils, at Week 4	0.045 10^9 cells/L	Standard Deviation 0.0644
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Monocytes, at Day 14	0.034 10^9 cells/L	Standard Deviation 0.1347
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Platelets, at Baseline	256.3 10^9 cells/L	Standard Deviation 48.96
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Eosinophils, at Week 16	0.059 10^9 cells/L	Standard Deviation 0.1667
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Basophils, at Week 16	-0.001 10^9 cells/L	Standard Deviation 0.0083
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Lymphocytes, at Week 4	0.063 10^9 cells/L	Standard Deviation 0.1943
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Basophils, at Week 24	0.000 10^9 cells/L	Standard Deviation 0.0151
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Basophils, at Day 7	0.008 10^9 cells/L	Standard Deviation 0.0128
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Lymphocytes, at Week 16	0.100 10^9 cells/L	Standard Deviation 0.2441
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Eosinophils, at Week 24	0.001 10^9 cells/L	Standard Deviation 0.1063
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Eosinophils, at Day 7	0.016 10^9 cells/L	Standard Deviation 0.0964
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Lymphocytes, at Week 24	0.058 10^9 cells/L	Standard Deviation 0.3377
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Platelets, at Day 2	6.6 10^9 cells/L	Standard Deviation 12.7
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Basophils, at Day 14	0.001 10^9 cells/L	Standard Deviation 0.0064
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Monocytes, at Baseline	0.396 10^9 cells/L	Standard Deviation 0.1556
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	WBC, at Baseline	5.13 10^9 cells/L	Standard Deviation 1.161
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Neutrophils, at Baseline	3.218 10^9 cells/L	Standard Deviation 0.9157
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Lymphocytes, at Day 7	-0.043 10^9 cells/L	Standard Deviation 0.1763
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Platelets, at Week 16	-0.5 10^9 cells/L	Standard Deviation 19.34
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Basophils, at Week 4	0.003 10^9 cells/L	Standard Deviation 0.0139
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	WBC, at Day 2	0.43 10^9 cells/L	Standard Deviation 0.696
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Monocytes, at Week 16	0.023 10^9 cells/L	Standard Deviation 0.063
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Monocytes, at Day 7	0.049 10^9 cells/L	Standard Deviation 0.1185
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	WBC, at Day 7	-0.04 10^9 cells/L	Standard Deviation 1.171
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	WBC, at Day 8	-0.05 10^9 cells/L	Standard Deviation 0.997
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	WBC, at Day 10	-0.85 10^9 cells/L	Standard Deviation 0.071
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	WBC, at Day 14	-0.38 10^9 cells/L	Standard Deviation 0.791
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Basophils, at Baseline	0.035 10^9 cells/L	Standard Deviation 0.0207
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	WBC, at Week 4	-0.40 10^9 cells/L	Standard Deviation 0.857
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	WBC, at Day 4	0.32 10^9 cells/L	Standard Deviation 1.386
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	WBC, at Week 24	0.40 10^9 cells/L	Standard Deviation 2.438
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Basophils, at Day 2	0.000 10^9 cells/L	Standard Deviation 0.0151
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Lymphocytes, at Baseline	2.214 10^9 cells/L	Standard Deviation 0.5545
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Lymphocytes, at Day 2	-0.484 10^9 cells/L	Standard Deviation 0.3503
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Basophils, at Day 3	0.005 10^9 cells/L	Standard Deviation 0.0152
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Lymphocytes, at Day 3	-0.175 10^9 cells/L	Standard Deviation 0.3459
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	WBC, at Week 16	-0.63 10^9 cells/L	Standard Deviation 1.073
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Lymphocytes, at Day 4	-0.065 10^9 cells/L	Standard Deviation 0.3551
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Basophils, at Day 4	0.012 10^9 cells/L	Standard Deviation 0.0172
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Lymphocytes, at Day 8	-0.193 10^9 cells/L	Standard Deviation 0.3462
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Lymphocytes, at Day 10	-0.475 10^9 cells/L	Standard Deviation 0.0778
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Basophils, at Day 8	0.002 10^9 cells/L	Standard Deviation 0.0098
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Lymphocytes, at Week 4	-0.314 10^9 cells/L	Standard Deviation 0.2911
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Lymphocytes, at Week 16	-0.190 10^9 cells/L	Standard Deviation 0.2478
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Basophils, at Day 10	0.000 10^9 cells/L	Standard Deviation 0.0283
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Lymphocytes, at Week 24	-0.380 10^9 cells/L	Standard Deviation 0.3497
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Monocytes, at Baseline	0.461 10^9 cells/L	Standard Deviation 0.1038
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Basophils, at Day 14	0.008 10^9 cells/L	Standard Deviation 0.0139
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Monocytes, at Day 3	0.040 10^9 cells/L	Standard Deviation 0.0639
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Monocytes, at Day 4	0.080 10^9 cells/L	Standard Deviation 0.0957
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Basophils, at Week 4	0.004 10^9 cells/L	Standard Deviation 0.0141
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	WBC, at Day 3	0.13 10^9 cells/L	Standard Deviation 1.113
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Lymphocytes, at Day 7	-0.211 10^9 cells/L	Standard Deviation 0.3189
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Monocytes, at Day 8	0.008 10^9 cells/L	Standard Deviation 0.1019
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Monocytes, at Day 10	-0.110 10^9 cells/L	Standard Deviation 0.1131
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Monocytes, at Day 14	-0.078 10^9 cells/L	Standard Deviation 0.1237
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Monocytes, at Week 4	-0.045 10^9 cells/L	Standard Deviation 0.1146
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Basophils, at Week 16	0.004 10^9 cells/L	Standard Deviation 0.0192
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Monocytes, at Week 16	-0.029 10^9 cells/L	Standard Deviation 0.1221
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Monocytes, at Week 24	0.001 10^9 cells/L	Standard Deviation 0.167
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Eosinophils, at Baseline	0.098 10^9 cells/L	Standard Deviation 0.0333
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Neutrophils, at Baseline	3.499 10^9 cells/L	Standard Deviation 0.9783
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Neutrophils, at Day 2	0.214 10^9 cells/L	Standard Deviation 1.0869
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Neutrophils, at Day 3	0.238 10^9 cells/L	Standard Deviation 0.9621
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Eosinophils, at Day 2	0.010 10^9 cells/L	Standard Deviation 0.0151
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Neutrophils, at Day 4	0.262 10^9 cells/L	Standard Deviation 1.073
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Lymphocytes, at Day 14	-0.386 10^9 cells/L	Standard Deviation 0.3366
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Neutrophils, at Day 8	0.160 10^9 cells/L	Standard Deviation 0.8802
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Neutrophils, at Day 10	-0.270 10^9 cells/L	Standard Deviation 0.3111
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Neutrophils, at Day 14	0.096 10^9 cells/L	Standard Deviation 0.8912
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Eosinophils, at Day 3	0.017 10^9 cells/L	Standard Deviation 0.0121
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Neutrophils, at Week 4	-0.036 10^9 cells/L	Standard Deviation 0.9269
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Neutrophils, at Week 16	-0.468 10^9 cells/L	Standard Deviation 0.9437
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Eosinophils, at Day 4	0.022 10^9 cells/L	Standard Deviation 0.0194
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Neutrophils, at Week 24	0.691 10^9 cells/L	Standard Deviation 2.3541
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Monocytes, at Day 2	-0.048 10^9 cells/L	Standard Deviation 0.1159
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Platelets, at Baseline	301.9 10^9 cells/L	Standard Deviation 34.84
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Platelets, at Day 2	-14.6 10^9 cells/L	Standard Deviation 12.95
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Eosinophils, at Day 7	0.000 10^9 cells/L	Standard Deviation 0.0293
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Platelets, at Day 3	3.2 10^9 cells/L	Standard Deviation 19.77
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Eosinophils, at Day 10	-0.010 10^9 cells/L	Standard Deviation 0.0424
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Platelets, at Day 4	-4.2 10^9 cells/L	Standard Deviation 17.22
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Platelets, at Day 7	0.0 10^9 cells/L	Standard Deviation 13.49
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Eosinophils, at Day 14	0.011 10^9 cells/L	Standard Deviation 0.0624
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Platelets, at Day 8	2.8 10^9 cells/L	Standard Deviation 12.14
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Platelets, at Day 10	-8.0 10^9 cells/L	Standard Deviation 19.8
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Platelets, at Day 14	1.0 10^9 cells/L	Standard Deviation 52.6
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Platelets, at Week 4	-3.5 10^9 cells/L	Standard Deviation 15.1
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Platelets, at Week 24	12.5 10^9 cells/L	Standard Deviation 37.14
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Basophils, at Day 7	0.003 10^9 cells/L	Standard Deviation 0.0128
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Eosinophils, at Week 4	0.001 10^9 cells/L	Standard Deviation 0.029
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Neutrophils, at Day 7	0.210 10^9 cells/L	Standard Deviation 0.9063
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Eosinophils, at Week 16	0.053 10^9 cells/L	Standard Deviation 0.1269
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Eosinophils, at Week 24	0.094 10^9 cells/L	Standard Deviation 0.1445
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Eosinophils, at Day 8	0.003 10^9 cells/L	Standard Deviation 0.032
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	WBC, at Baseline	6.31 10^9 cells/L	Standard Deviation 1.365
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	WBC, at Day 2	-0.31 10^9 cells/L	Standard Deviation 1.253
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Platelets, at Week 16	6.6 10^9 cells/L	Standard Deviation 35.49
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Monocytes, at Day 7	-0.021 10^9 cells/L	Standard Deviation 0.1572
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Basophils, at Week 24	0.001 10^9 cells/L	Standard Deviation 0.0259
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Platelets, at Week 24	-2.3 10^9 cells/L	Standard Deviation 27.79
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Basophils, at Day 7	-0.005 10^9 cells/L	Standard Deviation 0.0107
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Basophils, at Week 16	-0.001 10^9 cells/L	Standard Deviation 0.0121
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Basophils, at Week 24	-0.013 10^9 cells/L	Standard Deviation 0.016
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Eosinophils, at Day 7	0.016 10^9 cells/L	Standard Deviation 0.0619
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	WBC, at Day 3	-0.41 10^9 cells/L	Standard Deviation 1.089
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Lymphocytes, at Day 4	-0.106 10^9 cells/L	Standard Deviation 0.3847
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Neutrophils, at Day 7	-0.079 10^9 cells/L	Standard Deviation 1.848
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Platelets, at Week 4	3.1 10^9 cells/L	Standard Deviation 31.31
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Platelets, at Week 16	-6.4 10^9 cells/L	Standard Deviation 31.43
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Basophils, at Baseline	0.044 10^9 cells/L	Standard Deviation 0.0106
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Basophils, at Day 2	-0.009 10^9 cells/L	Standard Deviation 0.0083
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Basophils, at Day 3	-0.009 10^9 cells/L	Standard Deviation 0.0113
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Basophils, at Day 4	-0.001 10^9 cells/L	Standard Deviation 0.0181
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Basophils, at Day 14	0.003 10^9 cells/L	Standard Deviation 0.0149
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Basophils, at Week 4	0.000 10^9 cells/L	Standard Deviation 0.0185
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Eosinophils, at Baseline	0.145 10^9 cells/L	Standard Deviation 0.137
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Eosinophils, at Day 2	0.016 10^9 cells/L	Standard Deviation 0.0385
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Eosinophils, at Day 3	0.010 10^9 cells/L	Standard Deviation 0.0513
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Eosinophils, at Day 4	0.010 10^9 cells/L	Standard Deviation 0.0431
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Eosinophils, at Day 14	0.025 10^9 cells/L	Standard Deviation 0.0444
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Eosinophils, at Week 4	-0.004 10^9 cells/L	Standard Deviation 0.0403
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Eosinophils, at Week 16	0.013 10^9 cells/L	Standard Deviation 0.0605
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Eosinophils, at Week 24	-0.001 10^9 cells/L	Standard Deviation 0.0527
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	WBC, at Baseline	6.50 10^9 cells/L	Standard Deviation 2.036
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	WBC, at Day 2	-0.36 10^9 cells/L	Standard Deviation 0.98
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	WBC, at Day 4	-0.49 10^9 cells/L	Standard Deviation 1.36
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	WBC, at Day 7	-0.25 10^9 cells/L	Standard Deviation 2.165
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	WBC, at Day 14	-0.25 10^9 cells/L	Standard Deviation 0.994
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	WBC, at Week 4	-0.48 10^9 cells/L	Standard Deviation 1.34
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	WBC, at Week 16	-0.64 10^9 cells/L	Standard Deviation 1.162
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	WBC, at Week 24	-0.51 10^9 cells/L	Standard Deviation 0.54
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Lymphocytes, at Baseline	2.086 10^9 cells/L	Standard Deviation 0.4824
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Lymphocytes, at Day 2	-0.094 10^9 cells/L	Standard Deviation 0.2147
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Lymphocytes, at Day 3	-0.135 10^9 cells/L	Standard Deviation 0.2727
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Lymphocytes, at Day 7	-0.175 10^9 cells/L	Standard Deviation 0.3166
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Lymphocytes, at Day 14	-0.161 10^9 cells/L	Standard Deviation 0.3561
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Lymphocytes, at Week 4	-0.226 10^9 cells/L	Standard Deviation 0.2908
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Lymphocytes, at Week 16	-0.191 10^9 cells/L	Standard Deviation 0.3559
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Lymphocytes, at Week 24	-0.339 10^9 cells/L	Standard Deviation 0.4461
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Monocytes, at Baseline	0.485 10^9 cells/L	Standard Deviation 0.1488
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Monocytes, at Day 2	-0.008 10^9 cells/L	Standard Deviation 0.0587
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Monocytes, at Day 3	-0.013 10^9 cells/L	Standard Deviation 0.0886
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Monocytes, at Day 4	-0.006 10^9 cells/L	Standard Deviation 0.1034
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Monocytes, at Day 7	-0.013 10^9 cells/L	Standard Deviation 0.1413
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Monocytes, at Day 14	-0.015 10^9 cells/L	Standard Deviation 0.1319
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Monocytes, at Week 4	-0.034 10^9 cells/L	Standard Deviation 0.101
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Monocytes, at Week 16	0.001 10^9 cells/L	Standard Deviation 0.0724
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Monocytes, at Week 24	-0.020 10^9 cells/L	Standard Deviation 0.0462
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Neutrophils, at Baseline	3.756 10^9 cells/L	Standard Deviation 1.6757
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Neutrophils, at Day 2	-0.263 10^9 cells/L	Standard Deviation 0.9093
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Neutrophils, at Day 3	-0.291 10^9 cells/L	Standard Deviation 0.9503
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Neutrophils, at Day 4	-0.398 10^9 cells/L	Standard Deviation 1.0114
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Neutrophils, at Day 14	-0.116 10^9 cells/L	Standard Deviation 0.7571
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Neutrophils, at Week 4	-0.233 10^9 cells/L	Standard Deviation 1.1531
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Neutrophils, at Week 16	-0.500 10^9 cells/L	Standard Deviation 0.9401
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Neutrophils, at Week 24	-0.160 10^9 cells/L	Standard Deviation 0.634
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Platelets, at Baseline	289.5 10^9 cells/L	Standard Deviation 71.95
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Platelets, at Day 2	1.0 10^9 cells/L	Standard Deviation 18.48
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Platelets, at Day 3	0.1 10^9 cells/L	Standard Deviation 19.63
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Platelets, at Day 4	-4.9 10^9 cells/L	Standard Deviation 20.16
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Platelets, at Day 7	1.9 10^9 cells/L	Standard Deviation 23.46
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils	Platelets, at Day 14	2.1 10^9 cells/L	Standard Deviation 40.86

Secondary

Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)

ECG values were collected as assessed by protocol, at the indicated time points.

Time frame: From Baseline (Day -1) up to Week 24

Arm	Measure	Group	Value (MEAN)	Dispersion
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	QTcF Interval, at Day 4	-2.000 Miliseconds	Standard Deviation 15.0449
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	PR Interval, at Week 4	9.542 Miliseconds	Standard Deviation 5.9038
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	QTcF Interval, at Day 1	2.833 Miliseconds	Standard Deviation 10.057
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	QT Interval, at Day 1	0.708 Miliseconds	Standard Deviation 12.1713
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	PR Interval, at Week 24	4.583 Miliseconds	Standard Deviation 10.1164
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	QTcF Interval, at Day 7	8.667 Miliseconds	Standard Deviation 22.8341
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	QT Interval, at Baseline	378.875 Miliseconds	Standard Deviation 17.7719
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	QRS Interval, at Baseline	92.875 Miliseconds	Standard Deviation 8.1141
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	QTcF Interval, at Week 4	1.167 Miliseconds	Standard Deviation 10.6398
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	QRS Interval, at Week 4	0.708 Miliseconds	Standard Deviation 3.9337
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	QRS Interval, at Day 1	0.875 Miliseconds	Standard Deviation 3.5587
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	QRS Interval, at Day 7	0.000 Miliseconds	Standard Deviation 5.1052
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	QRS Interval, at Day 2	-2.292 Miliseconds	Standard Deviation 2.6693
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	QT Interval, at Day 2	4.750 Miliseconds	Standard Deviation 12.1299
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	QRS Interval, at Day 4	1.458 Miliseconds	Standard Deviation 5.0895
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	QRS Interval, at Day 3	-0.875 Miliseconds	Standard Deviation 2.3363
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	PR Interval, at Baseline	161.375 Miliseconds	Standard Deviation 20.2762
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	QTcF Interval, at Week 24	2.417 Miliseconds	Standard Deviation 10.5991
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	QTcF Interval, at Baseline	402.750 Miliseconds	Standard Deviation 10.5119
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	PR Interval, at Day 1	-4.000 Miliseconds	Standard Deviation 10.7157
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	QT Interval, at Week 4	14.083 Miliseconds	Standard Deviation 18.0614
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	PR Interval, at Day 2	-0.208 Miliseconds	Standard Deviation 7.5297
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	PR Interval, at Day 3	1.083 Miliseconds	Standard Deviation 7.8493
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	QTcF Interval, at Day 2	-1.875 Miliseconds	Standard Deviation 9.2923
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	QT Interval, at Day 7	7.042 Miliseconds	Standard Deviation 20.7972
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	PR Interval, at Day 4	4.625 Miliseconds	Standard Deviation 8.6179
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	QT Interval, at Week 24	15.125 Miliseconds	Standard Deviation 21.3348
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	QT Interval, at Day 4	5.917 Miliseconds	Standard Deviation 22.1616
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	PR Interval, at Day 7	1.458 Miliseconds	Standard Deviation 11.6223
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	QRS Interval, at Week 24	-0.917 Miliseconds	Standard Deviation 4.5066
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	QT Interval, at Day 3	8.583 Miliseconds	Standard Deviation 18.265
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	QTcF Interval, at Day 3	0.917 Miliseconds	Standard Deviation 9.5232
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	QT Interval, at Day 7	21.083 Miliseconds	Standard Deviation 21.4755
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	PR Interval, at Day 2	1.917 Miliseconds	Standard Deviation 9.5282
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	QT Interval, at Day 2	20.750 Miliseconds	Standard Deviation 18.9684
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	QT Interval, at Week 24	13.167 Miliseconds	Standard Deviation 21.5318
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	QTcF Interval, at Day 3	-1.250 Miliseconds	Standard Deviation 14.9047
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	QTcF Interval, at Week 4	6.500 Miliseconds	Standard Deviation 8.8515
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	PR Interval, at Baseline	164.000 Miliseconds	Standard Deviation 16.6733
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	PR Interval, at Day 3	3.000 Miliseconds	Standard Deviation 10.6354
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	PR Interval, at Day 4	0.875 Miliseconds	Standard Deviation 10.8656
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	PR Interval, at Day 7	6.167 Miliseconds	Standard Deviation 10.9516
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	PR Interval, at Day 8	5.875 Miliseconds	Standard Deviation 9.433
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	PR Interval, at Day 10	19.167 Miliseconds	Standard Deviation 8.721
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	PR Interval, at Week 4	4.250 Miliseconds	Standard Deviation 11.77
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	PR Interval, at Week 24	-0.958 Miliseconds	Standard Deviation 11.6571
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	QRS Interval, at Baseline	90.750 Miliseconds	Standard Deviation 11.8291
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	QRS Interval, at Day 2	-0.458 Miliseconds	Standard Deviation 3.7116
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	QRS Interval, at Day 3	-2.833 Miliseconds	Standard Deviation 6.2463
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	QRS Interval, at Day 4	-1.875 Miliseconds	Standard Deviation 6.0708
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	QRS Interval, at Day 7	-1.500 Miliseconds	Standard Deviation 6.8359
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	QRS Interval, at Day 8	-1.042 Miliseconds	Standard Deviation 4.6987
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	QRS Interval, at Day 10	-4.333 Miliseconds	Standard Deviation 6.5997
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	QRS Interval, at Week 4	-0.958 Miliseconds	Standard Deviation 3.8398
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	QRS Interval, at Week 24	-0.458 Miliseconds	Standard Deviation 4.4755
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	QT Interval, at Baseline	395.875 Miliseconds	Standard Deviation 19.1493
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	QT Interval, at Day 3	10.542 Miliseconds	Standard Deviation 27.0566
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	QT Interval, at Day 4	7.000 Miliseconds	Standard Deviation 27.0725
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	QT Interval, at Day 8	19.167 Miliseconds	Standard Deviation 20.0206
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	QT Interval, at Day 10	31.667 Miliseconds	Standard Deviation 55.1543
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	QT Interval, at Week 4	31.167 Miliseconds	Standard Deviation 17.0023
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	QTcF Interval, at Baseline	419.375 Miliseconds	Standard Deviation 13.7523
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	QTcF Interval, at Day 2	1.083 Miliseconds	Standard Deviation 15.4486
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	QTcF Interval, at Day 4	-4.292 Miliseconds	Standard Deviation 18.322
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	QTcF Interval, at Day 7	0.958 Miliseconds	Standard Deviation 9.6715
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	QTcF Interval, at Day 8	1.833 Miliseconds	Standard Deviation 14.841
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	QTcF Interval, at Day 10	0.667 Miliseconds	Standard Deviation 33.9411
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	QTcF Interval, at Week 24	2.229 Miliseconds	Standard Deviation 14.8754
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	PR Interval, at Day 7	2.625 Miliseconds	Standard Deviation 6.3507
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	QTcF Interval, at Day 2	3.375 Miliseconds	Standard Deviation 11.7924
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	QT Interval, at Day 3	9.792 Miliseconds	Standard Deviation 12.7179
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	PR Interval, at Day 4	3.000 Miliseconds	Standard Deviation 10.0775
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	QTcF Interval, at Day 3	2.083 Miliseconds	Standard Deviation 8.6295
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	QT Interval, at Day 4	9.167 Miliseconds	Standard Deviation 18.5267
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	PR Interval, at Day 3	3.667 Miliseconds	Standard Deviation 10.6845
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	PR Interval, at Day 2	3.500 Miliseconds	Standard Deviation 7.6677
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	QT Interval, at Day 7	8.500 Miliseconds	Standard Deviation 13.6498
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	QT Interval, at Week 24	15.952 Miliseconds	Standard Deviation 10.9771
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	QTcF Interval, at Week 24	7.238 Miliseconds	Standard Deviation 5.6461
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	PR Interval, at Day 1	0.500 Miliseconds	Standard Deviation 4.5145
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	QTcF Interval, at Week 4	2.250 Miliseconds	Standard Deviation 8.4867
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	QRS Interval, at Day 3	-2.583 Miliseconds	Standard Deviation 3.6764
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	QRS Interval, at Day 2	-3.708 Miliseconds	Standard Deviation 5.6833
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	PR Interval, at Baseline	164.875 Miliseconds	Standard Deviation 14.2872
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	QRS Interval, at Day 4	-4.458 Miliseconds	Standard Deviation 6.4855
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	QRS Interval, at Day 1	-5.250 Miliseconds	Standard Deviation 6.8098
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	QTcF Interval, at Day 7	3.500 Miliseconds	Standard Deviation 11.9004
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	QRS Interval, at Day 7	-2.917 Miliseconds	Standard Deviation 6.3164
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	QTcF Interval, at Baseline	397.000 Miliseconds	Standard Deviation 14.8131
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	QTcF Interval, at Day 4	1.917 Miliseconds	Standard Deviation 9.0847
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	QRS Interval, at Baseline	100.250 Miliseconds	Standard Deviation 12.1155
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	QTcF Interval, at Day 1	1.375 Miliseconds	Standard Deviation 9.178
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	QT Interval, at Week 4	10.583 Miliseconds	Standard Deviation 13.7318
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	QRS Interval, at Week 24	-5.238 Miliseconds	Standard Deviation 6.4599
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	PR Interval, at Week 24	-1.905 Miliseconds	Standard Deviation 12.0872
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	QRS Interval, at Week 4	-4.708 Miliseconds	Standard Deviation 6.2372
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	QT Interval, at Baseline	380.375 Miliseconds	Standard Deviation 12.3513
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	PR Interval, at Week 4	-2.250 Miliseconds	Standard Deviation 10.6231
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	QT Interval, at Day 1	-0.625 Miliseconds	Standard Deviation 8.662
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)	QT Interval, at Day 2	16.083 Miliseconds	Standard Deviation 13.6449

Secondary

Change From Baseline in Pulse Rate

Pulse rate was measured at the indicated time points, in a supine position after the participant has been at rest for at least 5 minutes in a quiet setting without distractions.

Time frame: From Baseline (Day -1) up to Week 24

Arm	Measure	Group	Value (MEAN)	Dispersion
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Pulse Rate	Week 24	-10.5 Beats per minute (Beats/min)	Standard Deviation 6.57
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Pulse Rate	Week 12	-4.8 Beats per minute (Beats/min)	Standard Deviation 10.44
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Pulse Rate	Day 7	-1.4 Beats per minute (Beats/min)	Standard Deviation 18.68
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Pulse Rate	Day 2	-4.4 Beats per minute (Beats/min)	Standard Deviation 6.74
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Pulse Rate	Week 8	-3.9 Beats per minute (Beats/min)	Standard Deviation 15.13
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Pulse Rate	Baseline	73.9 Beats per minute (Beats/min)	Standard Deviation 7.85
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Pulse Rate	Week 4	-7.3 Beats per minute (Beats/min)	Standard Deviation 3.28
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Pulse Rate	Day 21	-3.1 Beats per minute (Beats/min)	Standard Deviation 11.43
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Pulse Rate	Week 20	-9.0 Beats per minute (Beats/min)	Standard Deviation 8.14
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Pulse Rate	Day 3	-7.6 Beats per minute (Beats/min)	Standard Deviation 4.84
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Pulse Rate	Day 14	-4.5 Beats per minute (Beats/min)	Standard Deviation 7.6
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Pulse Rate	Week 16	-11.1 Beats per minute (Beats/min)	Standard Deviation 10.25
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Pulse Rate	Day 4	-6.4 Beats per minute (Beats/min)	Standard Deviation 7.76
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Pulse Rate	Week 12	-6.3 Beats per minute (Beats/min)	Standard Deviation 7.44
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Pulse Rate	Day 14	-10.0 Beats per minute (Beats/min)	Standard Deviation 6.72
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Pulse Rate	Baseline	71.1 Beats per minute (Beats/min)	Standard Deviation 7.16
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Pulse Rate	Day 2	-7.6 Beats per minute (Beats/min)	Standard Deviation 8.28
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Pulse Rate	Day 3	-5.4 Beats per minute (Beats/min)	Standard Deviation 9.01
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Pulse Rate	Day 4	-4.3 Beats per minute (Beats/min)	Standard Deviation 8.75
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Pulse Rate	Day 7	-9.4 Beats per minute (Beats/min)	Standard Deviation 6.95
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Pulse Rate	Day 8	-8.3 Beats per minute (Beats/min)	Standard Deviation 5.78
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Pulse Rate	Day 21	-9.1 Beats per minute (Beats/min)	Standard Deviation 5.06
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Pulse Rate	Week 4	-9.9 Beats per minute (Beats/min)	Standard Deviation 7.34
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Pulse Rate	Week 8	-8.0 Beats per minute (Beats/min)	Standard Deviation 8.09
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Pulse Rate	Day 10	-12.0 Beats per minute (Beats/min)	Standard Deviation 7.07
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Pulse Rate	Week 16	-5.1 Beats per minute (Beats/min)	Standard Deviation 8.61
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Pulse Rate	Week 20	-5.0 Beats per minute (Beats/min)	Standard Deviation 5.01
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Pulse Rate	Week 24	-4.3 Beats per minute (Beats/min)	Standard Deviation 4.8
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Pulse Rate	Week 8	-8.3 Beats per minute (Beats/min)	Standard Deviation 15.75
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Pulse Rate	Day 4	-8.1 Beats per minute (Beats/min)	Standard Deviation 11.52
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Pulse Rate	Week 20	-12.4 Beats per minute (Beats/min)	Standard Deviation 8.06
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Pulse Rate	Week 12	-9.8 Beats per minute (Beats/min)	Standard Deviation 14.21
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Pulse Rate	Day 3	-12.1 Beats per minute (Beats/min)	Standard Deviation 8.63
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Pulse Rate	Baseline	75.9 Beats per minute (Beats/min)	Standard Deviation 12.26
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Pulse Rate	Week 16	-10.6 Beats per minute (Beats/min)	Standard Deviation 10.66
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Pulse Rate	Day 21	-11.0 Beats per minute (Beats/min)	Standard Deviation 18.45
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Pulse Rate	Day 14	-11.4 Beats per minute (Beats/min)	Standard Deviation 16.95
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Pulse Rate	Day 2	-13.8 Beats per minute (Beats/min)	Standard Deviation 10.66
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Pulse Rate	Week 4	-13.4 Beats per minute (Beats/min)	Standard Deviation 12.05
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Pulse Rate	Day 7	-8.4 Beats per minute (Beats/min)	Standard Deviation 14.81
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Pulse Rate	Week 24	-15.3 Beats per minute (Beats/min)	Standard Deviation 11.5

Secondary

Change From Baseline in Red Blood Cell Count (RBC)

Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of VH3810109.

Time frame: From Baseline (Day -1) up to Week 24

Arm	Measure	Group	Value (MEAN)	Dispersion
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Red Blood Cell Count (RBC)	Baseline	4.518 Trillion cells/L (TI/L)	Standard Deviation 0.5518
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Red Blood Cell Count (RBC)	Day 7	0.155 Trillion cells/L (TI/L)	Standard Deviation 0.2067
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Red Blood Cell Count (RBC)	Day 14	0.130 Trillion cells/L (TI/L)	Standard Deviation 0.1646
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Red Blood Cell Count (RBC)	Day 2	0.180 Trillion cells/L (TI/L)	Standard Deviation 0.2654
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Red Blood Cell Count (RBC)	Week 16	0.186 Trillion cells/L (TI/L)	Standard Deviation 0.2612
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Red Blood Cell Count (RBC)	Week 4	0.050 Trillion cells/L (TI/L)	Standard Deviation 0.1802
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Red Blood Cell Count (RBC)	Week 24	0.063 Trillion cells/L (TI/L)	Standard Deviation 0.1496
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Red Blood Cell Count (RBC)	Day 3	0.163 Trillion cells/L (TI/L)	Standard Deviation 0.3064
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Red Blood Cell Count (RBC)	Day 4	0.085 Trillion cells/L (TI/L)	Standard Deviation 0.2239
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Red Blood Cell Count (RBC)	Day 7	0.084 Trillion cells/L (TI/L)	Standard Deviation 0.1584
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Red Blood Cell Count (RBC)	Day 8	0.088 Trillion cells/L (TI/L)	Standard Deviation 0.1877
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Red Blood Cell Count (RBC)	Day 10	-0.315 Trillion cells/L (TI/L)	Standard Deviation 0.1626
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Red Blood Cell Count (RBC)	Day 14	-0.088 Trillion cells/L (TI/L)	Standard Deviation 0.194
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Red Blood Cell Count (RBC)	Week 4	-0.026 Trillion cells/L (TI/L)	Standard Deviation 0.1625
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Red Blood Cell Count (RBC)	Week 24	0.078 Trillion cells/L (TI/L)	Standard Deviation 0.2326
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Red Blood Cell Count (RBC)	Baseline	4.523 Trillion cells/L (TI/L)	Standard Deviation 0.4014
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Red Blood Cell Count (RBC)	Day 2	0.043 Trillion cells/L (TI/L)	Standard Deviation 0.1717
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Red Blood Cell Count (RBC)	Week 16	0.124 Trillion cells/L (TI/L)	Standard Deviation 0.2212
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Red Blood Cell Count (RBC)	Day 3	0.079 Trillion cells/L (TI/L)	Standard Deviation 0.189
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Red Blood Cell Count (RBC)	Week 24	-0.110 Trillion cells/L (TI/L)	Standard Deviation 0.3089
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Red Blood Cell Count (RBC)	Day 4	0.056 Trillion cells/L (TI/L)	Standard Deviation 0.2169
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Red Blood Cell Count (RBC)	Day 2	0.141 Trillion cells/L (TI/L)	Standard Deviation 0.2154
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Red Blood Cell Count (RBC)	Baseline	4.889 Trillion cells/L (TI/L)	Standard Deviation 0.6362
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Red Blood Cell Count (RBC)	Week 4	-0.078 Trillion cells/L (TI/L)	Standard Deviation 0.1814
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Red Blood Cell Count (RBC)	Day 14	-0.064 Trillion cells/L (TI/L)	Standard Deviation 0.1686
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Red Blood Cell Count (RBC)	Week 16	-0.164 Trillion cells/L (TI/L)	Standard Deviation 0.0752
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Red Blood Cell Count (RBC)	Day 7	-0.074 Trillion cells/L (TI/L)	Standard Deviation 0.1429

Secondary

Change From Baseline in Respiratory Rate

Respiratory rate was measured at the indicated time points, in a supine position after the participant has been at rest for at least 5 minutes in a quiet setting without distractions.

Time frame: From Baseline (Day -1) up to Week 24

Arm	Measure	Group	Value (MEAN)	Dispersion
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Respiratory Rate	Week 4	1.3 Breaths per minute (Breaths/min)	Standard Deviation 2.38
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Respiratory Rate	Day 21	-1.3 Breaths per minute (Breaths/min)	Standard Deviation 2.6
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Respiratory Rate	Day 4	-2.0 Breaths per minute (Breaths/min)	Standard Deviation 2.14
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Respiratory Rate	Week 16	-2.0 Breaths per minute (Breaths/min)	Standard Deviation 4.28
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Respiratory Rate	Day 14	-1.5 Breaths per minute (Breaths/min)	Standard Deviation 2.98
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Respiratory Rate	Day 7	0.8 Breaths per minute (Breaths/min)	Standard Deviation 4.77
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Respiratory Rate	Day 1/4 Hours Postdose	-1.4 Breaths per minute (Breaths/min)	Standard Deviation 1.9
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Respiratory Rate	Day 3	-1.3 Breaths per minute (Breaths/min)	Standard Deviation 2.12
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Respiratory Rate	Week 20	-0.9 Breaths per minute (Breaths/min)	Standard Deviation 3.8
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Respiratory Rate	Week 12	-1.0 Breaths per minute (Breaths/min)	Standard Deviation 2.14
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Respiratory Rate	Day 1/8 Hours Postdose	1.5 Breaths per minute (Breaths/min)	Standard Deviation 2.56
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Respiratory Rate	Baseline	15.5 Breaths per minute (Breaths/min)	Standard Deviation 1.41
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Respiratory Rate	Week 8	1.0 Breaths per minute (Breaths/min)	Standard Deviation 2.83
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Respiratory Rate	Day 2	-1.3 Breaths per minute (Breaths/min)	Standard Deviation 3.2
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Respiratory Rate	Week 24	-3.3 Breaths per minute (Breaths/min)	Standard Deviation 2.38
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Respiratory Rate	Day 8	-0.8 Breaths per minute (Breaths/min)	Standard Deviation 5.01
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Respiratory Rate	Day 3	-1.5 Breaths per minute (Breaths/min)	Standard Deviation 4.24
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Respiratory Rate	Baseline	15.8 Breaths per minute (Breaths/min)	Standard Deviation 3.77
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Respiratory Rate	Day 1/4 Hours Postdose	-0.3 Breaths per minute (Breaths/min)	Standard Deviation 3.45
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Respiratory Rate	Day 1/8 Hours Postdose	-2.3 Breaths per minute (Breaths/min)	Standard Deviation 2.25
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Respiratory Rate	Day 2	-2.0 Breaths per minute (Breaths/min)	Standard Deviation 3.85
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Respiratory Rate	Day 4	-1.5 Breaths per minute (Breaths/min)	Standard Deviation 3.16
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Respiratory Rate	Day 7	-2.8 Breaths per minute (Breaths/min)	Standard Deviation 4.89
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Respiratory Rate	Day 10	0.0 Breaths per minute (Breaths/min)	Standard Deviation 5.66
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Respiratory Rate	Day 14	-2.0 Breaths per minute (Breaths/min)	Standard Deviation 3.38
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Respiratory Rate	Day 21	-2.3 Breaths per minute (Breaths/min)	Standard Deviation 2.92
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Respiratory Rate	Week 4	-2.0 Breaths per minute (Breaths/min)	Standard Deviation 4.41
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Respiratory Rate	Week 8	-2.3 Breaths per minute (Breaths/min)	Standard Deviation 4.59
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Respiratory Rate	Week 12	-2.5 Breaths per minute (Breaths/min)	Standard Deviation 3.34
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Respiratory Rate	Week 16	-2.5 Breaths per minute (Breaths/min)	Standard Deviation 5.42
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Respiratory Rate	Week 20	-1.0 Breaths per minute (Breaths/min)	Standard Deviation 3.21
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Respiratory Rate	Week 24	-2.5 Breaths per minute (Breaths/min)	Standard Deviation 1.77
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Respiratory Rate	Week 16	3.1 Breaths per minute (Breaths/min)	Standard Deviation 1.95
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Respiratory Rate	Week 4	1.0 Breaths per minute (Breaths/min)	Standard Deviation 2.83
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Respiratory Rate	Day 1/8 Hours Postdose	0.8 Breaths per minute (Breaths/min)	Standard Deviation 3.85
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Respiratory Rate	Week 24	0.3 Breaths per minute (Breaths/min)	Standard Deviation 2.93
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Respiratory Rate	Week 8	1.3 Breaths per minute (Breaths/min)	Standard Deviation 1.83
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Respiratory Rate	Day 1/4 Hours Postdose	2.0 Breaths per minute (Breaths/min)	Standard Deviation 3.38
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Respiratory Rate	Day 7	-0.3 Breaths per minute (Breaths/min)	Standard Deviation 2.92
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Respiratory Rate	Week 20	1.1 Breaths per minute (Breaths/min)	Standard Deviation 3.98
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Respiratory Rate	Day 4	0.0 Breaths per minute (Breaths/min)	Standard Deviation 2.62
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Respiratory Rate	Week 12	1.5 Breaths per minute (Breaths/min)	Standard Deviation 2.33
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Respiratory Rate	Day 14	-1.3 Breaths per minute (Breaths/min)	Standard Deviation 2.12
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Respiratory Rate	Day 3	2.3 Breaths per minute (Breaths/min)	Standard Deviation 2.71
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Respiratory Rate	Baseline	13.8 Breaths per minute (Breaths/min)	Standard Deviation 1.98
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Respiratory Rate	Day 21	1.0 Breaths per minute (Breaths/min)	Standard Deviation 3.85
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Respiratory Rate	Day 2	1.3 Breaths per minute (Breaths/min)	Standard Deviation 2.12

Secondary

Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide

Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of VH3810109.

Time frame: From Baseline (Day -1) up to Week 24

Arm	Measure	Group	Value (MEAN)	Dispersion
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Chloride, at Day 2	-0.6 Millimole per liter (mmol/L)	Standard Deviation 2.45
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Chloride, at Week 24	-0.1 Millimole per liter (mmol/L)	Standard Deviation 2.36
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Calcium, at Day 2	-0.015594 Millimole per liter (mmol/L)	Standard Deviation 0.1041067
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Calcium, at Day 14	0.009356 Millimole per liter (mmol/L)	Standard Deviation 0.0398698
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Chloride, at Week 16	-0.4 Millimole per liter (mmol/L)	Standard Deviation 2.13
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Chloride, at Day 7	-0.5 Millimole per liter (mmol/L)	Standard Deviation 1.07
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Chloride, at Week 4	-1.3 Millimole per liter (mmol/L)	Standard Deviation 2.38
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Sodium, at Week 16	-0.8 Millimole per liter (mmol/L)	Standard Deviation 1.58
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Chloride, at Day 14	-1.6 Millimole per liter (mmol/L)	Standard Deviation 1.77
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Calcium, at Day 7	-0.012475 Millimole per liter (mmol/L)	Standard Deviation 0.0533453
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Potassium, at Day 2	0.09 Millimole per liter (mmol/L)	Standard Deviation 0.242
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Calcium, at Week 16	-0.015594 Millimole per liter (mmol/L)	Standard Deviation 0.0842805
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Chloride, at Baseline	103.1 Millimole per liter (mmol/L)	Standard Deviation 1.81
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Calcium, at Week 24	-0.056138 Millimole per liter (mmol/L)	Standard Deviation 0.0861717
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Sodium, at Day 7	-0.5 Millimole per liter (mmol/L)	Standard Deviation 1.77
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Carbon Dioxide, at Week 24	-0.5 Millimole per liter (mmol/L)	Standard Deviation 1.2
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Carbon Dioxide, at Baseline	29.4 Millimole per liter (mmol/L)	Standard Deviation 1.77
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Sodium, at Week 24	-1.1 Millimole per liter (mmol/L)	Standard Deviation 2.53
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Carbon Dioxide, at Week 16	-1.3 Millimole per liter (mmol/L)	Standard Deviation 1.28
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Carbon Dioxide, at Day 2	0.5 Millimole per liter (mmol/L)	Standard Deviation 1.41
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Sodium, at Day 2	-0.4 Millimole per liter (mmol/L)	Standard Deviation 2.13
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Carbon Dioxide, at Week 4	1.5 Millimole per liter (mmol/L)	Standard Deviation 1.51
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Sodium, at Week 4	-0.9 Millimole per liter (mmol/L)	Standard Deviation 2.17
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Carbon Dioxide, at Day 7	-0.3 Millimole per liter (mmol/L)	Standard Deviation 1.39
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Sodium, at Baseline	138.8 Millimole per liter (mmol/L)	Standard Deviation 1.39
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Potassium, at Week 16	-0.38 Millimole per liter (mmol/L)	Standard Deviation 0.413
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Calcium, at Week 4	-0.031188 Millimole per liter (mmol/L)	Standard Deviation 0.0739536
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Potassium, at Week 4	-0.16 Millimole per liter (mmol/L)	Standard Deviation 0.389
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Potassium, at Week 24	-0.06 Millimole per liter (mmol/L)	Standard Deviation 0.245
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Carbon Dioxide, at Day 14	0.3 Millimole per liter (mmol/L)	Standard Deviation 0.89
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Potassium, at Day 14	-0.13 Millimole per liter (mmol/L)	Standard Deviation 0.381
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Sodium, at Day 14	-1.3 Millimole per liter (mmol/L)	Standard Deviation 1.39
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Potassium, at Day 7	-0.30 Millimole per liter (mmol/L)	Standard Deviation 0.421
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Potassium, at Baseline	4.36 Millimole per liter (mmol/L)	Standard Deviation 0.484
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Calcium, at Baseline	2.329706 Millimole per liter (mmol/L)	Standard Deviation 0.1049575
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Sodium, at Day 14	1.0 Millimole per liter (mmol/L)	Standard Deviation 2.88
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Calcium, at Day 8	-0.004158 Millimole per liter (mmol/L)	Standard Deviation 0.0639356
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Calcium, at Day 10	-0.112275 Millimole per liter (mmol/L)	Standard Deviation 0.0882116
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Calcium, at Day 14	-0.034306 Millimole per liter (mmol/L)	Standard Deviation 0.0923367
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Calcium, at Week 4	-0.034306 Millimole per liter (mmol/L)	Standard Deviation 0.0853291
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Carbon Dioxide, at Day 7	0.3 Millimole per liter (mmol/L)	Standard Deviation 1.28
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Carbon Dioxide, at Day 10	0.0 Millimole per liter (mmol/L)	Standard Deviation 1.41
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Chloride, at Day 2	0.0 Millimole per liter (mmol/L)	Standard Deviation 2
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Chloride, at Day 7	0.1 Millimole per liter (mmol/L)	Standard Deviation 1.64
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Potassium, at Day 2	0.16 Millimole per liter (mmol/L)	Standard Deviation 0.325
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Potassium, at Day 4	0.00 Millimole per liter (mmol/L)	Standard Deviation 0.544
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Potassium, at Week 4	0.18 Millimole per liter (mmol/L)	Standard Deviation 0.183
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Potassium, at Week 16	0.11 Millimole per liter (mmol/L)	Standard Deviation 0.189
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Sodium, at Day 2	-0.4 Millimole per liter (mmol/L)	Standard Deviation 2.26
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Calcium, at Baseline	2.317231 Millimole per liter (mmol/L)	Standard Deviation 0.0805028
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Calcium, at Day 2	-0.003119 Millimole per liter (mmol/L)	Standard Deviation 0.0983979
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Calcium, at Day 3	0.037425 Millimole per liter (mmol/L)	Standard Deviation 0.1101762
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Calcium, at Day 4	0.008317 Millimole per liter (mmol/L)	Standard Deviation 0.1145166
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Calcium, at Day 7	-0.006238 Millimole per liter (mmol/L)	Standard Deviation 0.083018
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Calcium, at Week 16	0.018713 Millimole per liter (mmol/L)	Standard Deviation 0.0751464
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Calcium, at Week 24	-0.031188 Millimole per liter (mmol/L)	Standard Deviation 0.0371268
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Carbon Dioxide, at Baseline	27.8 Millimole per liter (mmol/L)	Standard Deviation 2.25
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Carbon Dioxide, at Day 2	0.6 Millimole per liter (mmol/L)	Standard Deviation 1.19
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Carbon Dioxide, at Day 3	1.5 Millimole per liter (mmol/L)	Standard Deviation 0.84
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Carbon Dioxide, at Day 4	1.3 Millimole per liter (mmol/L)	Standard Deviation 1.03
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Carbon Dioxide, at Day 8	1.3 Millimole per liter (mmol/L)	Standard Deviation 1.03
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Carbon Dioxide, at Day 14	0.5 Millimole per liter (mmol/L)	Standard Deviation 1.51
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Carbon Dioxide, at Week 4	0.9 Millimole per liter (mmol/L)	Standard Deviation 1.64
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Carbon Dioxide, at Week 16	0.3 Millimole per liter (mmol/L)	Standard Deviation 0.71
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Carbon Dioxide, at Week 24	0.4 Millimole per liter (mmol/L)	Standard Deviation 1.51
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Chloride, at Baseline	102.1 Millimole per liter (mmol/L)	Standard Deviation 2.59
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Chloride, at Day 3	-1.2 Millimole per liter (mmol/L)	Standard Deviation 1.94
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Chloride, at Day 4	-1.5 Millimole per liter (mmol/L)	Standard Deviation 1.64
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Chloride, at Day 8	0.3 Millimole per liter (mmol/L)	Standard Deviation 1.75
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Chloride, at Day 10	5.5 Millimole per liter (mmol/L)	Standard Deviation 2.12
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Chloride, at Day 14	1.0 Millimole per liter (mmol/L)	Standard Deviation 2.56
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Chloride, at Week 4	1.1 Millimole per liter (mmol/L)	Standard Deviation 2.47
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Chloride, at Week 16	1.5 Millimole per liter (mmol/L)	Standard Deviation 1.41
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Chloride, at Week 24	0.6 Millimole per liter (mmol/L)	Standard Deviation 2.26
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Potassium, at Baseline	4.14 Millimole per liter (mmol/L)	Standard Deviation 0.342
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Potassium, at Day 3	0.13 Millimole per liter (mmol/L)	Standard Deviation 0.372
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Potassium, at Day 7	0.29 Millimole per liter (mmol/L)	Standard Deviation 0.47
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Potassium, at Day 8	0.07 Millimole per liter (mmol/L)	Standard Deviation 0.207
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Potassium, at Day 10	0.45 Millimole per liter (mmol/L)	Standard Deviation 0.354
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Potassium, at Day 14	0.04 Millimole per liter (mmol/L)	Standard Deviation 0.513
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Potassium, at Week 24	-0.03 Millimole per liter (mmol/L)	Standard Deviation 0.354
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Sodium, at Baseline	137.1 Millimole per liter (mmol/L)	Standard Deviation 2.23
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Sodium, at Day 3	-0.8 Millimole per liter (mmol/L)	Standard Deviation 0.98
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Sodium, at Day 4	-1.3 Millimole per liter (mmol/L)	Standard Deviation 2.25
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Sodium, at Day 7	0.5 Millimole per liter (mmol/L)	Standard Deviation 2.2
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Sodium, at Day 8	0.3 Millimole per liter (mmol/L)	Standard Deviation 1.51
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Sodium, at Day 10	4.5 Millimole per liter (mmol/L)	Standard Deviation 4.95
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Sodium, at Week 4	1.0 Millimole per liter (mmol/L)	Standard Deviation 2.45
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Sodium, at Week 16	1.0 Millimole per liter (mmol/L)	Standard Deviation 2.51
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Sodium, at Week 24	0.1 Millimole per liter (mmol/L)	Standard Deviation 3.48
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Chloride, at Week 4	0.4 Millimole per liter (mmol/L)	Standard Deviation 1.06
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Calcium, at Day 2	-0.003119 Millimole per liter (mmol/L)	Standard Deviation 0.0983979
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Calcium, at Day 14	-0.009356 Millimole per liter (mmol/L)	Standard Deviation 0.0923367
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Chloride, at Week 16	0.7 Millimole per liter (mmol/L)	Standard Deviation 1.8
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Calcium, at Baseline	2.351538 Millimole per liter (mmol/L)	Standard Deviation 0.0931159
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Sodium, at Day 3	-0.3 Millimole per liter (mmol/L)	Standard Deviation 1.49
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Chloride, at Week 24	1.7 Millimole per liter (mmol/L)	Standard Deviation 2.21
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Sodium, at Day 14	0.6 Millimole per liter (mmol/L)	Standard Deviation 1.85
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Sodium, at Week 4	0.9 Millimole per liter (mmol/L)	Standard Deviation 1.64
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Potassium, at Baseline	4.29 Millimole per liter (mmol/L)	Standard Deviation 0.485
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Sodium, at Day 4	-0.1 Millimole per liter (mmol/L)	Standard Deviation 1.89
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Potassium, at Day 3	0.14 Millimole per liter (mmol/L)	Standard Deviation 0.25
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Calcium, at Day 7	0.037425 Millimole per liter (mmol/L)	Standard Deviation 0.0442316
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Potassium, at Day 2	0.10 Millimole per liter (mmol/L)	Standard Deviation 0.366
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Potassium, at Day 7	-0.01 Millimole per liter (mmol/L)	Standard Deviation 0.34
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Carbon Dioxide, at Day 4	0.3 Millimole per liter (mmol/L)	Standard Deviation 1.28
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Carbon Dioxide, at Day 3	-0.5 Millimole per liter (mmol/L)	Standard Deviation 0.93
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Calcium, at Week 4	0.003119 Millimole per liter (mmol/L)	Standard Deviation 0.0826826
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Sodium, at Day 7	0.8 Millimole per liter (mmol/L)	Standard Deviation 1.98
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Carbon Dioxide, at Day 14	-0.4 Millimole per liter (mmol/L)	Standard Deviation 1.41
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Carbon Dioxide, at Day 2	0.4 Millimole per liter (mmol/L)	Standard Deviation 1.41
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Sodium, at Day 2	0.1 Millimole per liter (mmol/L)	Standard Deviation 2.3
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Carbon Dioxide, at Week 4	0.0 Millimole per liter (mmol/L)	Standard Deviation 0.93
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Carbon Dioxide, at Baseline	28.6 Millimole per liter (mmol/L)	Standard Deviation 1.92
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Sodium, at Week 24	2.0 Millimole per liter (mmol/L)	Standard Deviation 2.24
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Carbon Dioxide, at Week 16	-0.4 Millimole per liter (mmol/L)	Standard Deviation 0.98
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Calcium, at Week 24	-0.053464 Millimole per liter (mmol/L)	Standard Deviation 0.1002445
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Potassium, at Day 14	0.09 Millimole per liter (mmol/L)	Standard Deviation 0.458
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Carbon Dioxide, at Week 24	0.3 Millimole per liter (mmol/L)	Standard Deviation 1.38
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Calcium, at Week 16	-0.064157 Millimole per liter (mmol/L)	Standard Deviation 0.0496021
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Potassium, at Week 16	-0.04 Millimole per liter (mmol/L)	Standard Deviation 0.382
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Chloride, at Baseline	102.4 Millimole per liter (mmol/L)	Standard Deviation 2.2
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Chloride, at Day 2	0.1 Millimole per liter (mmol/L)	Standard Deviation 2.42
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Sodium, at Week 16	1.3 Millimole per liter (mmol/L)	Standard Deviation 1.6
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Chloride, at Day 3	-0.3 Millimole per liter (mmol/L)	Standard Deviation 2.49
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Potassium, at Week 24	0.01 Millimole per liter (mmol/L)	Standard Deviation 0.308
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Chloride, at Day 4	-0.4 Millimole per liter (mmol/L)	Standard Deviation 2.39
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Chloride, at Day 7	0.5 Millimole per liter (mmol/L)	Standard Deviation 2.14
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Potassium, at Week 4	-0.01 Millimole per liter (mmol/L)	Standard Deviation 0.196
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Carbon Dioxide, at Day 7	0.3 Millimole per liter (mmol/L)	Standard Deviation 0.71
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Calcium, at Day 4	0.040544 Millimole per liter (mmol/L)	Standard Deviation 0.07297
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Sodium, at Baseline	136.9 Millimole per liter (mmol/L)	Standard Deviation 2.53
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Chloride, at Day 14	0.4 Millimole per liter (mmol/L)	Standard Deviation 2.13
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Calcium, at Day 3	0.003119 Millimole per liter (mmol/L)	Standard Deviation 0.0759557
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide	Potassium, at Day 4	0.13 Millimole per liter (mmol/L)	Standard Deviation 0.32

Secondary

Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)

Blood pressure was measured at the indicated time points, in a supine position after the participant has been at rest for at least 5 minutes in a quiet setting without distractions.

Time frame: From Baseline (Day -1) up to Week 24

Arm	Measure	Group	Value (MEAN)	Dispersion
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	Diastolic Blood Pressure, at Week 16	3.8 Millimeters of mercury (mmHg)	Standard Deviation 3.15
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	Diastolic Blood Pressure, at Day 14	1.6 Millimeters of mercury (mmHg)	Standard Deviation 6.63
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	Systolic Blood Pressure, at Week 8	9.0 Millimeters of mercury (mmHg)	Standard Deviation 17.02
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	Systolic Blood Pressure, at Day 4	-0.5 Millimeters of mercury (mmHg)	Standard Deviation 9.2
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	Diastolic Blood Pressure, at Day 7	1.9 Millimeters of mercury (mmHg)	Standard Deviation 8.32
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	Systolic Blood Pressure, at Week 12	-3.8 Millimeters of mercury (mmHg)	Standard Deviation 4.89
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	Diastolic Blood Pressure, at Week 24	1.5 Millimeters of mercury (mmHg)	Standard Deviation 4.28
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	Diastolic Blood Pressure, at Day 4	0.6 Millimeters of mercury (mmHg)	Standard Deviation 6.05
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	Systolic Blood Pressure, at Week 16	4.6 Millimeters of mercury (mmHg)	Standard Deviation 5.55
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	Diastolic Blood Pressure, at Week 12	0.5 Millimeters of mercury (mmHg)	Standard Deviation 4.96
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	Diastolic Blood Pressure, at Day 2	-1.6 Millimeters of mercury (mmHg)	Standard Deviation 5.48
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	Systolic Blood Pressure, at Week 20	-2.1 Millimeters of mercury (mmHg)	Standard Deviation 14.28
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	Systolic Blood Pressure, at Day 7	2.1 Millimeters of mercury (mmHg)	Standard Deviation 8.18
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	Diastolic Blood Pressure, at Baseline	66.5 Millimeters of mercury (mmHg)	Standard Deviation 9.71
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	Systolic Blood Pressure, at Week 24	2.0 Millimeters of mercury (mmHg)	Standard Deviation 7.78
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	Systolic Blood Pressure, at Day 2	-4.1 Millimeters of mercury (mmHg)	Standard Deviation 12.24
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	Diastolic Blood Pressure, at Week 8	6.4 Millimeters of mercury (mmHg)	Standard Deviation 7.74
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	Systolic Blood Pressure, at Baseline	112.8 Millimeters of mercury (mmHg)	Standard Deviation 12.67
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	Diastolic Blood Pressure, at Week 20	-2.0 Millimeters of mercury (mmHg)	Standard Deviation 7.09
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	Systolic Blood Pressure, at Day 14	2.4 Millimeters of mercury (mmHg)	Standard Deviation 8.68
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	Systolic Blood Pressure, at Day 3	-2.9 Millimeters of mercury (mmHg)	Standard Deviation 7.49
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	Diastolic Blood Pressure, at Week 4	2.1 Millimeters of mercury (mmHg)	Standard Deviation 7.24
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	Systolic Blood Pressure, at Day 21	5.4 Millimeters of mercury (mmHg)	Standard Deviation 10.21
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	Diastolic Blood Pressure, at Day 3	2.4 Millimeters of mercury (mmHg)	Standard Deviation 4.87
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	Diastolic Blood Pressure, at Day 21	2.8 Millimeters of mercury (mmHg)	Standard Deviation 6.5
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	Systolic Blood Pressure, at Week 4	-0.9 Millimeters of mercury (mmHg)	Standard Deviation 8.54
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	Diastolic Blood Pressure, at Week 12	6.8 Millimeters of mercury (mmHg)	Standard Deviation 7.15
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	Systolic Blood Pressure, at Baseline	106.3 Millimeters of mercury (mmHg)	Standard Deviation 11.68
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	Systolic Blood Pressure, at Day 2	3.5 Millimeters of mercury (mmHg)	Standard Deviation 8.04
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	Systolic Blood Pressure, at Day 3	0.8 Millimeters of mercury (mmHg)	Standard Deviation 5.99
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	Systolic Blood Pressure, at Day 4	0.3 Millimeters of mercury (mmHg)	Standard Deviation 6.45
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	Systolic Blood Pressure, at Day 7	2.1 Millimeters of mercury (mmHg)	Standard Deviation 6.03
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	Systolic Blood Pressure, at Day 8	-2.4 Millimeters of mercury (mmHg)	Standard Deviation 8.47
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	Systolic Blood Pressure, at Day 10	4.5 Millimeters of mercury (mmHg)	Standard Deviation 13.44
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	Systolic Blood Pressure, at Day 14	11.3 Millimeters of mercury (mmHg)	Standard Deviation 9.19
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	Systolic Blood Pressure, at Day 21	9.8 Millimeters of mercury (mmHg)	Standard Deviation 13.36
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	Systolic Blood Pressure, at Week 4	9.5 Millimeters of mercury (mmHg)	Standard Deviation 11.8
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	Systolic Blood Pressure, at Week 8	9.5 Millimeters of mercury (mmHg)	Standard Deviation 14.43
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	Systolic Blood Pressure, at Week 12	4.5 Millimeters of mercury (mmHg)	Standard Deviation 16.38
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	Systolic Blood Pressure, at Week 16	7.9 Millimeters of mercury (mmHg)	Standard Deviation 11.08
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	Systolic Blood Pressure, at Week 20	2.1 Millimeters of mercury (mmHg)	Standard Deviation 10.83
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	Systolic Blood Pressure, at Week 24	6.4 Millimeters of mercury (mmHg)	Standard Deviation 10.07
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	Diastolic Blood Pressure, at Baseline	59.8 Millimeters of mercury (mmHg)	Standard Deviation 6.45
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	Diastolic Blood Pressure, at Day 2	3.4 Millimeters of mercury (mmHg)	Standard Deviation 8.23
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	Diastolic Blood Pressure, at Day 3	1.1 Millimeters of mercury (mmHg)	Standard Deviation 7.24
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	Diastolic Blood Pressure, at Day 4	-2.3 Millimeters of mercury (mmHg)	Standard Deviation 4.62
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	Diastolic Blood Pressure, at Day 7	-1.6 Millimeters of mercury (mmHg)	Standard Deviation 4.41
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	Diastolic Blood Pressure, at Day 8	-1.8 Millimeters of mercury (mmHg)	Standard Deviation 3.96
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	Diastolic Blood Pressure, at Day 10	9.0 Millimeters of mercury (mmHg)	Standard Deviation 8.49
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	Diastolic Blood Pressure, at Day 14	6.1 Millimeters of mercury (mmHg)	Standard Deviation 3.72
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	Diastolic Blood Pressure, at Day 21	10.6 Millimeters of mercury (mmHg)	Standard Deviation 8.37
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	Diastolic Blood Pressure, at Week 4	8.1 Millimeters of mercury (mmHg)	Standard Deviation 6.4
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	Diastolic Blood Pressure, at Week 8	9.1 Millimeters of mercury (mmHg)	Standard Deviation 3.44
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	Diastolic Blood Pressure, at Week 16	9.1 Millimeters of mercury (mmHg)	Standard Deviation 5.11
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	Diastolic Blood Pressure, at Week 20	6.3 Millimeters of mercury (mmHg)	Standard Deviation 5.55
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	Diastolic Blood Pressure, at Week 24	7.4 Millimeters of mercury (mmHg)	Standard Deviation 6.57
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	Systolic Blood Pressure, at Day 3	-4.5 Millimeters of mercury (mmHg)	Standard Deviation 4.66
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	Systolic Blood Pressure, at Baseline	114.4 Millimeters of mercury (mmHg)	Standard Deviation 9.5
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	Systolic Blood Pressure, at Week 4	2.8 Millimeters of mercury (mmHg)	Standard Deviation 7.85
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	Diastolic Blood Pressure, at Week 16	8.4 Millimeters of mercury (mmHg)	Standard Deviation 6.73
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	Diastolic Blood Pressure, at Day 14	6.1 Millimeters of mercury (mmHg)	Standard Deviation 5.33
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	Systolic Blood Pressure, at Day 21	7.8 Millimeters of mercury (mmHg)	Standard Deviation 11.5
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	Systolic Blood Pressure, at Day 2	-4.5 Millimeters of mercury (mmHg)	Standard Deviation 7.19
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	Diastolic Blood Pressure, at Day 21	12.9 Millimeters of mercury (mmHg)	Standard Deviation 4.67
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	Systolic Blood Pressure, at Day 14	6.5 Millimeters of mercury (mmHg)	Standard Deviation 10.38
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	Diastolic Blood Pressure, at Week 24	12.1 Millimeters of mercury (mmHg)	Standard Deviation 7.49
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	Diastolic Blood Pressure, at Week 4	7.6 Millimeters of mercury (mmHg)	Standard Deviation 6.32
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	Systolic Blood Pressure, at Day 7	3.6 Millimeters of mercury (mmHg)	Standard Deviation 8.28
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	Systolic Blood Pressure, at Week 24	-0.1 Millimeters of mercury (mmHg)	Standard Deviation 4.91
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	Systolic Blood Pressure, at Week 20	6.3 Millimeters of mercury (mmHg)	Standard Deviation 7.83
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	Diastolic Blood Pressure, at Week 20	13.6 Millimeters of mercury (mmHg)	Standard Deviation 6.19
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	Diastolic Blood Pressure, at Baseline	62.1 Millimeters of mercury (mmHg)	Standard Deviation 5.59
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	Systolic Blood Pressure, at Week 16	-0.3 Millimeters of mercury (mmHg)	Standard Deviation 10.27
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	Diastolic Blood Pressure, at Week 8	7.6 Millimeters of mercury (mmHg)	Standard Deviation 3.29
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	Systolic Blood Pressure, at Day 4	-5.6 Millimeters of mercury (mmHg)	Standard Deviation 6.23
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	Diastolic Blood Pressure, at Day 3	-1.9 Millimeters of mercury (mmHg)	Standard Deviation 5.51
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	Systolic Blood Pressure, at Week 12	7.9 Millimeters of mercury (mmHg)	Standard Deviation 11.54
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	Diastolic Blood Pressure, at Day 2	-0.5 Millimeters of mercury (mmHg)	Standard Deviation 6.89
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	Diastolic Blood Pressure, at Day 4	-0.8 Millimeters of mercury (mmHg)	Standard Deviation 4.86
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	Systolic Blood Pressure, at Week 8	5.6 Millimeters of mercury (mmHg)	Standard Deviation 7.58
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	Diastolic Blood Pressure, at Week 12	11.5 Millimeters of mercury (mmHg)	Standard Deviation 7.78
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	Diastolic Blood Pressure, at Day 7	9.5 Millimeters of mercury (mmHg)	Standard Deviation 9.78

Secondary

Change From Baseline in Temperature

Temperature was measured at the indicated time points, in a supine position after the participant has been at rest for at least 5 minutes in a quiet setting without distractions.

Time frame: From Baseline (Day -1) up to Week 24

Arm	Measure	Group	Value (MEAN)	Dispersion
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Temperature	Day 7	-0.05 Degrees Celcius	Standard Deviation 0.524
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Temperature	Day 3	-0.23 Degrees Celcius	Standard Deviation 0.365
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Temperature	Week 4	-0.21 Degrees Celcius	Standard Deviation 0.364
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Temperature	Week 12	-0.23 Degrees Celcius	Standard Deviation 0.271
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Temperature	Week 8	-0.28 Degrees Celcius	Standard Deviation 0.399
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Temperature	Week 20	-0.17 Degrees Celcius	Standard Deviation 0.315
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Temperature	Baseline	36.54 Degrees Celcius	Standard Deviation 0.233
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Temperature	Day 14	-0.13 Degrees Celcius	Standard Deviation 0.392
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Temperature	Week 24	-0.19 Degrees Celcius	Standard Deviation 0.364
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Temperature	Day 21	-0.11 Degrees Celcius	Standard Deviation 0.554
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Temperature	Week 16	-0.34 Degrees Celcius	Standard Deviation 0.346
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Temperature	Day 2	-0.10 Degrees Celcius	Standard Deviation 0.424
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Change From Baseline in Temperature	Day 4	-0.03 Degrees Celcius	Standard Deviation 0.311
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Temperature	Week 12	-0.33 Degrees Celcius	Standard Deviation 0.607
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Temperature	Day 7	-0.41 Degrees Celcius	Standard Deviation 0.622
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Temperature	Week 4	-0.56 Degrees Celcius	Standard Deviation 0.534
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Temperature	Day 4	-0.41 Degrees Celcius	Standard Deviation 0.569
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Temperature	Baseline	36.79 Degrees Celcius	Standard Deviation 0.344
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Temperature	Day 2	-0.48 Degrees Celcius	Standard Deviation 0.437
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Temperature	Day 3	-0.50 Degrees Celcius	Standard Deviation 0.475
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Temperature	Day 8	-0.41 Degrees Celcius	Standard Deviation 0.599
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Temperature	Day 10	-0.60 Degrees Celcius	Standard Deviation 0.566
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Temperature	Day 14	-0.28 Degrees Celcius	Standard Deviation 0.492
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Temperature	Day 21	-0.49 Degrees Celcius	Standard Deviation 0.352
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Temperature	Week 8	-0.45 Degrees Celcius	Standard Deviation 0.535
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Temperature	Week 16	-0.33 Degrees Celcius	Standard Deviation 0.575
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Temperature	Week 20	-0.40 Degrees Celcius	Standard Deviation 0.414
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Temperature	Week 24	-0.55 Degrees Celcius	Standard Deviation 0.678
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Temperature	Week 8	-0.20 Degrees Celcius	Standard Deviation 0.566
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Temperature	Day 4	-0.20 Degrees Celcius	Standard Deviation 0.463
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Temperature	Day 2	-0.14 Degrees Celcius	Standard Deviation 0.342
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Temperature	Week 12	-0.28 Degrees Celcius	Standard Deviation 0.423
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Temperature	Baseline	36.49 Degrees Celcius	Standard Deviation 0.5
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Temperature	Week 4	-0.09 Degrees Celcius	Standard Deviation 0.549
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Temperature	Week 16	-0.69 Degrees Celcius	Standard Deviation 0.534
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Temperature	Day 3	-0.25 Degrees Celcius	Standard Deviation 0.454
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Temperature	Day 14	-0.28 Degrees Celcius	Standard Deviation 0.453
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Temperature	Week 24	0.09 Degrees Celcius	Standard Deviation 0.367
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Temperature	Day 21	-0.04 Degrees Celcius	Standard Deviation 0.469
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Temperature	Day 7	-0.04 Degrees Celcius	Standard Deviation 0.578
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Change From Baseline in Temperature	Week 20	-0.19 Degrees Celcius	Standard Deviation 0.505

Secondary

Maximum Observed Concentration (Cmax) of VH3810109

Blood samples were collected as assessed by protocol, at specific time points for PK analysis of VH3810109.

Time frame: Up to Week 24

Arm	Measure	Value (MEAN)
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Maximum Observed Concentration (Cmax) of VH3810109	148.2 μg/mL
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Maximum Observed Concentration (Cmax) of VH3810109	1864 μg/mL
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Maximum Observed Concentration (Cmax) of VH3810109	321.1 μg/mL

Secondary

Number of ISRs Events Overall and by Grade (Part 1 and 3)

ISRs were recorded via ISR diaries and managed through investigator assessment. Severity of injection site reactions was analyzed using DAIDS AE Grading Table. The severity was categorized into grades as following: Grade 1 (mild): causing no or minimal interference with usual social and functional activities, Grade 2 (moderate): causing greater than minimal interference with usual social and functional activities, Grade 3 (severe): causing inability to perform usual social and functional activities, Grade 4 (Potentially life threatening): causing inability to perform basic self-care functions or hospitalization indicated, Grade 5 (death). Higher grade indicates more severe condition.

Time frame: Up to day 14

Population: Analysis was performed on the Safety set which included all participants that received at least one dose of the study intervention and had data for the assessed timepoints and analysis.

Arm	Measure	Group	Value (COUNT_OF_UNITS)
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Number of ISRs Events Overall and by Grade (Part 1 and 3)	Grade 4 ISRs	0 Number of events
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Number of ISRs Events Overall and by Grade (Part 1 and 3)	Grade 5 ISRs	0 Number of events
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Number of ISRs Events Overall and by Grade (Part 1 and 3)	Grade 3 ISRs	7 Number of events
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Number of ISRs Events Overall and by Grade (Part 1 and 3)	Grade 2 ISRs	5 Number of events
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Number of ISRs Events Overall and by Grade (Part 1 and 3)	Grade 1 ISRs	2 Number of events
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Number of ISRs Events Overall and by Grade (Part 1 and 3)	Overall ISRs	14 Number of events
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Number of ISRs Events Overall and by Grade (Part 1 and 3)	Grade 5 ISRs	0 Number of events
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Number of ISRs Events Overall and by Grade (Part 1 and 3)	Overall ISRs	18 Number of events
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Number of ISRs Events Overall and by Grade (Part 1 and 3)	Grade 1 ISRs	6 Number of events
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Number of ISRs Events Overall and by Grade (Part 1 and 3)	Grade 2 ISRs	2 Number of events
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Number of ISRs Events Overall and by Grade (Part 1 and 3)	Grade 3 ISRs	10 Number of events
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Number of ISRs Events Overall and by Grade (Part 1 and 3)	Grade 4 ISRs	0 Number of events

Secondary

Number of Participants Reporting Being Bothered or Affected by the Pain and Local Reactions Based on the PIN Questionaire (Part 1 and 3)

The PIN questionnaire measure contains 21 items: pain at injection site, local site reactions, impact on functioning and willingness to pursue injectable treatment outside clinical trial. Scores range from 1 to 5; the scores are defind as following: 1=totaly acceptable, 2=very acceptable, 3=moderately acceptable, 4=a little acceptable, 5=not at all acceptable; questions are phrased to ensure that 1: most favorable perception of vaccination, and 5: most unfavorable. Score of a dimension is calculated as mean of all items with dimension. Higher scores represent worse perception of injection.

Time frame: At Day 2 and Day 7

Population: Analysis was performed on the Safety Set which included all participants that received at least one dose of the study intervention and had data for the assessed timepoints and analysis.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Number of Participants Reporting Being Bothered or Affected by the Pain and Local Reactions Based on the PIN Questionaire (Part 1 and 3)	Totally acceptable local reactions, Day 2	7 Participants
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Number of Participants Reporting Being Bothered or Affected by the Pain and Local Reactions Based on the PIN Questionaire (Part 1 and 3)	Not at all acceptable local reactions, Day 2	0 Participants
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Number of Participants Reporting Being Bothered or Affected by the Pain and Local Reactions Based on the PIN Questionaire (Part 1 and 3)	Very acceptable local reactions, Day 7	2 Participants
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Number of Participants Reporting Being Bothered or Affected by the Pain and Local Reactions Based on the PIN Questionaire (Part 1 and 3)	Moderately acceptable local reactions, Day 7	1 Participants
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Number of Participants Reporting Being Bothered or Affected by the Pain and Local Reactions Based on the PIN Questionaire (Part 1 and 3)	Not at all acceptable local reactions, Day 7	0 Participants
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Number of Participants Reporting Being Bothered or Affected by the Pain and Local Reactions Based on the PIN Questionaire (Part 1 and 3)	A little acceptable pain, Day 2	1 Participants
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Number of Participants Reporting Being Bothered or Affected by the Pain and Local Reactions Based on the PIN Questionaire (Part 1 and 3)	Not at all acceptable pain, Day 2	0 Participants
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Number of Participants Reporting Being Bothered or Affected by the Pain and Local Reactions Based on the PIN Questionaire (Part 1 and 3)	Very acceptable local reactions, Day 2	0 Participants
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Number of Participants Reporting Being Bothered or Affected by the Pain and Local Reactions Based on the PIN Questionaire (Part 1 and 3)	Moderately acceptable local reactions, Day 2	0 Participants
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Number of Participants Reporting Being Bothered or Affected by the Pain and Local Reactions Based on the PIN Questionaire (Part 1 and 3)	A little acceptable local reactions, Day 2	1 Participants
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Number of Participants Reporting Being Bothered or Affected by the Pain and Local Reactions Based on the PIN Questionaire (Part 1 and 3)	Totally acceptable local reactions, Day 7	5 Participants
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Number of Participants Reporting Being Bothered or Affected by the Pain and Local Reactions Based on the PIN Questionaire (Part 1 and 3)	A little acceptable local reactions, Day 7	0 Participants
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Number of Participants Reporting Being Bothered or Affected by the Pain and Local Reactions Based on the PIN Questionaire (Part 1 and 3)	Totally acceptable pain, Day 2	6 Participants
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Number of Participants Reporting Being Bothered or Affected by the Pain and Local Reactions Based on the PIN Questionaire (Part 1 and 3)	Very acceptable pain, Day 2	1 Participants
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Number of Participants Reporting Being Bothered or Affected by the Pain and Local Reactions Based on the PIN Questionaire (Part 1 and 3)	Moderately acceptable pain, Day 2	0 Participants
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Number of Participants Reporting Being Bothered or Affected by the Pain and Local Reactions Based on the PIN Questionaire (Part 1 and 3)	Totally acceptable pain, Day 7	6 Participants
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Number of Participants Reporting Being Bothered or Affected by the Pain and Local Reactions Based on the PIN Questionaire (Part 1 and 3)	Very acceptable pain, Day 7	1 Participants
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Number of Participants Reporting Being Bothered or Affected by the Pain and Local Reactions Based on the PIN Questionaire (Part 1 and 3)	Moderately acceptable pain, Day 7	1 Participants
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Number of Participants Reporting Being Bothered or Affected by the Pain and Local Reactions Based on the PIN Questionaire (Part 1 and 3)	A little acceptable pain, Day 7	0 Participants
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Number of Participants Reporting Being Bothered or Affected by the Pain and Local Reactions Based on the PIN Questionaire (Part 1 and 3)	Not at all acceptable pain, Day 7	0 Participants
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Number of Participants Reporting Being Bothered or Affected by the Pain and Local Reactions Based on the PIN Questionaire (Part 1 and 3)	Totally acceptable pain, Day 2	4 Participants
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Number of Participants Reporting Being Bothered or Affected by the Pain and Local Reactions Based on the PIN Questionaire (Part 1 and 3)	Very acceptable local reactions, Day 2	1 Participants
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Number of Participants Reporting Being Bothered or Affected by the Pain and Local Reactions Based on the PIN Questionaire (Part 1 and 3)	Moderately acceptable local reactions, Day 2	1 Participants
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Number of Participants Reporting Being Bothered or Affected by the Pain and Local Reactions Based on the PIN Questionaire (Part 1 and 3)	A little acceptable local reactions, Day 2	0 Participants
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Number of Participants Reporting Being Bothered or Affected by the Pain and Local Reactions Based on the PIN Questionaire (Part 1 and 3)	Totally acceptable local reactions, Day 7	6 Participants
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Number of Participants Reporting Being Bothered or Affected by the Pain and Local Reactions Based on the PIN Questionaire (Part 1 and 3)	Not at all acceptable local reactions, Day 2	0 Participants
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Number of Participants Reporting Being Bothered or Affected by the Pain and Local Reactions Based on the PIN Questionaire (Part 1 and 3)	Very acceptable pain, Day 7	1 Participants
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Number of Participants Reporting Being Bothered or Affected by the Pain and Local Reactions Based on the PIN Questionaire (Part 1 and 3)	Moderately acceptable local reactions, Day 7	1 Participants
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Number of Participants Reporting Being Bothered or Affected by the Pain and Local Reactions Based on the PIN Questionaire (Part 1 and 3)	Very acceptable local reactions, Day 7	1 Participants
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Number of Participants Reporting Being Bothered or Affected by the Pain and Local Reactions Based on the PIN Questionaire (Part 1 and 3)	Moderately acceptable pain, Day 2	0 Participants
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Number of Participants Reporting Being Bothered or Affected by the Pain and Local Reactions Based on the PIN Questionaire (Part 1 and 3)	Very acceptable pain, Day 2	4 Participants
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Number of Participants Reporting Being Bothered or Affected by the Pain and Local Reactions Based on the PIN Questionaire (Part 1 and 3)	A little acceptable pain, Day 2	0 Participants
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Number of Participants Reporting Being Bothered or Affected by the Pain and Local Reactions Based on the PIN Questionaire (Part 1 and 3)	A little acceptable local reactions, Day 7	0 Participants
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Number of Participants Reporting Being Bothered or Affected by the Pain and Local Reactions Based on the PIN Questionaire (Part 1 and 3)	Not at all acceptable pain, Day 2	0 Participants
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Number of Participants Reporting Being Bothered or Affected by the Pain and Local Reactions Based on the PIN Questionaire (Part 1 and 3)	Totally acceptable pain, Day 7	5 Participants
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Number of Participants Reporting Being Bothered or Affected by the Pain and Local Reactions Based on the PIN Questionaire (Part 1 and 3)	Moderately acceptable pain, Day 7	2 Participants
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Number of Participants Reporting Being Bothered or Affected by the Pain and Local Reactions Based on the PIN Questionaire (Part 1 and 3)	A little acceptable pain, Day 7	0 Participants
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Number of Participants Reporting Being Bothered or Affected by the Pain and Local Reactions Based on the PIN Questionaire (Part 1 and 3)	Totally acceptable local reactions, Day 2	6 Participants
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Number of Participants Reporting Being Bothered or Affected by the Pain and Local Reactions Based on the PIN Questionaire (Part 1 and 3)	Not at all acceptable local reactions, Day 7	0 Participants
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Number of Participants Reporting Being Bothered or Affected by the Pain and Local Reactions Based on the PIN Questionaire (Part 1 and 3)	Not at all acceptable pain, Day 7	0 Participants

Secondary

Number of Participants Reporting Pain, Using Perception of Injection (PIN) Questionnaire (Part 1 and 3)

The PIN questionnaire measure contains 21 items: pain at injection site, local site reactions, impact on functioning and willingness to pursue injectable treatment outside clinical trial. Scores range from 1 to 5; the scores are defined as following: 1=not at all bothered, 2=a little bothered, 3=moderately bothered, 4=very bothered, 5=extremely bothered; questions are phrased to ensure that 1: most favorable perception of vaccination, and 5: most unfavorable. Score of a dimension is calculated as mean of all items with dimension. Higher scores represent worse perception of injection.

Time frame: At Day 2 and Day 7

Population: Analysis was performed on the Safety Set which included all participants that received at least one dose of the study intervention and had data for the assessed timepoints and analysis.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Number of Participants Reporting Pain, Using Perception of Injection (PIN) Questionnaire (Part 1 and 3)	A little bothered by pain, Day 2	2 Participants
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Number of Participants Reporting Pain, Using Perception of Injection (PIN) Questionnaire (Part 1 and 3)	Moderately bothered by pain, Day 2	0 Participants
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Number of Participants Reporting Pain, Using Perception of Injection (PIN) Questionnaire (Part 1 and 3)	Very bothered by pain, Day 2	0 Participants
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Number of Participants Reporting Pain, Using Perception of Injection (PIN) Questionnaire (Part 1 and 3)	Extremely bothered by pain, Day 2	0 Participants
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Number of Participants Reporting Pain, Using Perception of Injection (PIN) Questionnaire (Part 1 and 3)	A little bothered by pain, Day 7	3 Participants
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Number of Participants Reporting Pain, Using Perception of Injection (PIN) Questionnaire (Part 1 and 3)	Very bothered by pain, Day 7	0 Participants
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Number of Participants Reporting Pain, Using Perception of Injection (PIN) Questionnaire (Part 1 and 3)	Not at all bothered by pain, Day 2	6 Participants
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Number of Participants Reporting Pain, Using Perception of Injection (PIN) Questionnaire (Part 1 and 3)	Not at all bothered by pain, Day 7	5 Participants
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Number of Participants Reporting Pain, Using Perception of Injection (PIN) Questionnaire (Part 1 and 3)	Moderately bothered by pain, Day 7	0 Participants
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Number of Participants Reporting Pain, Using Perception of Injection (PIN) Questionnaire (Part 1 and 3)	Extremely bothered by pain, Day 7	0 Participants
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Number of Participants Reporting Pain, Using Perception of Injection (PIN) Questionnaire (Part 1 and 3)	Very bothered by pain, Day 7	0 Participants
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Number of Participants Reporting Pain, Using Perception of Injection (PIN) Questionnaire (Part 1 and 3)	A little bothered by pain, Day 2	2 Participants
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Number of Participants Reporting Pain, Using Perception of Injection (PIN) Questionnaire (Part 1 and 3)	Extremely bothered by pain, Day 7	0 Participants
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Number of Participants Reporting Pain, Using Perception of Injection (PIN) Questionnaire (Part 1 and 3)	Not at all bothered by pain, Day 7	5 Participants
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Number of Participants Reporting Pain, Using Perception of Injection (PIN) Questionnaire (Part 1 and 3)	Very bothered by pain, Day 2	0 Participants
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Number of Participants Reporting Pain, Using Perception of Injection (PIN) Questionnaire (Part 1 and 3)	Not at all bothered by pain, Day 2	6 Participants
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Number of Participants Reporting Pain, Using Perception of Injection (PIN) Questionnaire (Part 1 and 3)	Extremely bothered by pain, Day 2	0 Participants
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Number of Participants Reporting Pain, Using Perception of Injection (PIN) Questionnaire (Part 1 and 3)	Moderately bothered by pain, Day 2	0 Participants
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Number of Participants Reporting Pain, Using Perception of Injection (PIN) Questionnaire (Part 1 and 3)	A little bothered by pain, Day 7	3 Participants
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Number of Participants Reporting Pain, Using Perception of Injection (PIN) Questionnaire (Part 1 and 3)	Moderately bothered by pain, Day 7	0 Participants

Secondary

Number of Participants With Worst Case Urinalysis at Post-baseline Compared With Baseline

Urine samples were collected as assessed by protocol, at specific time points for laboratory analysis of VH3810109. At baseline and post-baseline, worst case urinalysis data was determined by comparing the resulted values of the urinalysis for each participant to the normal rage. This endpoint evaluates the changes from baseline for the worst case urinalysis.

Time frame: Day 14 compared with baseline (Day -1)

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Number of Participants With Worst Case Urinalysis at Post-baseline Compared With Baseline	Leukocyte esterase	0 Participants
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Number of Participants With Worst Case Urinalysis at Post-baseline Compared With Baseline	Protein	0 Participants
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Number of Participants With Worst Case Urinalysis at Post-baseline Compared With Baseline	Glucose	1 Participants
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Number of Participants With Worst Case Urinalysis at Post-baseline Compared With Baseline	Leukocyte esterase	1 Participants
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Number of Participants With Worst Case Urinalysis at Post-baseline Compared With Baseline	Glucose	0 Participants
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Number of Participants With Worst Case Urinalysis at Post-baseline Compared With Baseline	Protein	1 Participants
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Number of Participants With Worst Case Urinalysis at Post-baseline Compared With Baseline	Leukocyte esterase	1 Participants
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Number of Participants With Worst Case Urinalysis at Post-baseline Compared With Baseline	Glucose	0 Participants
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Number of Participants With Worst Case Urinalysis at Post-baseline Compared With Baseline	Protein	1 Participants

Secondary

Score Recorded for Acceptance of ISRs, Using Perception of Injection (PIN) Questionnaire (Part 1 and 3)

The PIN questionnaire measure contains 21 items: pain at injection site, local site reactions, impact on functioning and willingness to pursue injectable treatment outside clinical trial. Scores range from 1 to 5; questions are phrased to ensure that 1: most favorable perception of vaccination, and 5: most unfavorable. Score of a dimension is calculated as mean of all items with dimension. Higher scores represent worse perception of injection.

Time frame: At Day 2 and Day 7

Population: Analysis was performed on the Safety Set which included all participants that received at least one dose of the study intervention and had data for the assessed timepoints and analysis.

Arm	Measure	Group	Value (MEAN)	Dispersion
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Score Recorded for Acceptance of ISRs, Using Perception of Injection (PIN) Questionnaire (Part 1 and 3)	Acceptance of ISRs, Day 2	1.44 Scores on a scale	Standard Deviation 1.05
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Score Recorded for Acceptance of ISRs, Using Perception of Injection (PIN) Questionnaire (Part 1 and 3)	Acceptance of ISRs, Day 7	1.44 Scores on a scale	Standard Deviation 0.729
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Score Recorded for Acceptance of ISRs, Using Perception of Injection (PIN) Questionnaire (Part 1 and 3)	Acceptance of ISRs, Day 7	1.50 Scores on a scale	Standard Deviation 0.802
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Score Recorded for Acceptance of ISRs, Using Perception of Injection (PIN) Questionnaire (Part 1 and 3)	Acceptance of ISRs, Day 2	1.44 Scores on a scale	Standard Deviation 0.496

Secondary

Score Reported for Post-injection Pain Assessment Using Numeric Rating Scale (NRS) Following VH3810109 SC Administration (Part 1 and 3)

Post-injection assessment of pain was measured based on NRS which is a 11-point numerical rating scale ranging from 0 (no pain) to 10 (worst possible pain).

Time frame: At Day 1, Day 2 and Day 7

Population: Analysis was performed on the Safety set which included all participants that received at least one dose of the study intervention and had data for the assessed timepoints and analysis.

Arm	Measure	Group	Value (MEAN)	Dispersion
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Score Reported for Post-injection Pain Assessment Using Numeric Rating Scale (NRS) Following VH3810109 SC Administration (Part 1 and 3)	Day 1	3.63 Scores on a scale	Standard Deviation 2.326
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Score Reported for Post-injection Pain Assessment Using Numeric Rating Scale (NRS) Following VH3810109 SC Administration (Part 1 and 3)	Day 2	3.63 Scores on a scale	Standard Deviation 2.615
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Score Reported for Post-injection Pain Assessment Using Numeric Rating Scale (NRS) Following VH3810109 SC Administration (Part 1 and 3)	Day 7	3.63 Scores on a scale	Standard Deviation 2.925
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Score Reported for Post-injection Pain Assessment Using Numeric Rating Scale (NRS) Following VH3810109 SC Administration (Part 1 and 3)	Day 1	2.75 Scores on a scale	Standard Deviation 2.55
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Score Reported for Post-injection Pain Assessment Using Numeric Rating Scale (NRS) Following VH3810109 SC Administration (Part 1 and 3)	Day 2	0.63 Scores on a scale	Standard Deviation 0.744
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Score Reported for Post-injection Pain Assessment Using Numeric Rating Scale (NRS) Following VH3810109 SC Administration (Part 1 and 3)	Day 7	0.38 Scores on a scale	Standard Deviation 0.744

Secondary

Scores Reported for Post-injection Pain Assessment Using Numeric Rating Scale (NRS) Following VH3810109 IV Administration (Part 2)

Post-injection assessment of pain was measured based on NRS which is a 11-point numerical rating scale ranging from 0 (no pain) to 10 (worst possible pain).

Time frame: At Day 1, Day 2 and Day 7

Population: Analysis was performed on the Safety set which included all participants that received at least one dose of the study intervention and had data for the assessed timepoints and analysis.

Arm	Measure	Group	Value (MEAN)	Dispersion
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Scores Reported for Post-injection Pain Assessment Using Numeric Rating Scale (NRS) Following VH3810109 IV Administration (Part 2)	Day 1	0.50 Scores on a scale	Standard Deviation 1.069
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Scores Reported for Post-injection Pain Assessment Using Numeric Rating Scale (NRS) Following VH3810109 IV Administration (Part 2)	Day 2	0.88 Scores on a scale	Standard Deviation 1.642
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Scores Reported for Post-injection Pain Assessment Using Numeric Rating Scale (NRS) Following VH3810109 IV Administration (Part 2)	Day 7	0.50 Scores on a scale	Standard Deviation 1.414

Secondary

The Overall Duration of ISRs, Expressed in Days

ISRs will be recorded via ISR diaries and managed through investigator assessment.

Time frame: From Day 1 up to Day 14

Population: Analysis was performed on the Safety set which included all participants that received at least one dose of the study intervention and had data for the assessed timepoints and analysis.

Arm	Measure	Value (MEAN)	Dispersion
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	The Overall Duration of ISRs, Expressed in Days	2.9 Days	Standard Deviation 1.35
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	The Overall Duration of ISRs, Expressed in Days	4.6 Days	Standard Deviation 6.29

Secondary

Time of Maximum Observed Concentration (Tmax) of VH3810109

Blood samples were collected as assessed by protocol, at specific time points for PK analysis of VH3810109.

Time frame: Up to Week 24

Arm	Measure	Value (MEAN)
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]	Time of Maximum Observed Concentration (Tmax) of VH3810109	4.503 Days
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Time of Maximum Observed Concentration (Tmax) of VH3810109	0.046 Days
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]	Time of Maximum Observed Concentration (Tmax) of VH3810109	2.882 Days

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026

A Study to Investigate the Safety and Pharmacokinetics of a Single Dose of VH3810109 (Also Known as GSK3810109), Administered Either Subcutaneously (SC) With rHuPH20 or Intravenously (IV), in Healthy Adult Participants

Conditions

Keywords

Brief summary

Related papers

Interventions

Sponsors

Study design

Masking description

Intervention model description

Eligibility

Inclusion criteria

Exclusion criteria

Design outcomes

Primary

Secondary

Countries

Participant flow

Participants by arm

Withdrawals & dropouts

Baseline characteristics

Adverse events

Outcome results

Number of Participants With >= Grade 2 AEs Following IV Administration of VH3810109 (Part 2)

Number of Participants With Grade 2 or Higher (>=) Adverse Events (AEs) Following SC Administration of VH3810109 (Part 1 and Part 3)

Number of Participants With Grade 2 to 4 Elevated Alanin Aminotransferase/Aspartate Aminotransferase (ALT/AST) Values Following VH3810109 SC Administration (Part 1 and 3)

Number of Participants With Grade 2 to 4 Elevated ALT/AST Values Following VH3810109 IV Administration (Part 2)

Number of Participants With Injection Site Reactions (ISRs) Following VH3810109 SC Administration (Part 1 and 3)

Number of Participants With SAEs Following IV Administration of VH3810109 (Part 2)

Number of Participants With Serious Adverse Events (SAEs) Following SC Administration of VH3810109 (Part 1 and Part 3)

Apparent Terminal Phase Half-life (t1/2) of VH3810109

Area Under the Plasma Concentration-time Curve (AUC) From Time Zero Extrapolated to Infinity (AUC[0-inf]) of VH3810109

AUC From Time Zero to Time t (AUC[0-t]) of VH3810109

Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)

Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin

Change From Baseline in Hematocrit

Change From Baseline in Hemoglobin, Albumin and Total Protein

Change From Baseline in Mean Corpuscle Hemoglobin (MCH)

Change From Baseline in Mean Corpuscle Volume (MCV)

Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils

Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)

Change From Baseline in Pulse Rate

Change From Baseline in Red Blood Cell Count (RBC)

Change From Baseline in Respiratory Rate

Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide

Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)

Change From Baseline in Temperature

Maximum Observed Concentration (Cmax) of VH3810109

Number of ISRs Events Overall and by Grade (Part 1 and 3)

Number of Participants Reporting Being Bothered or Affected by the Pain and Local Reactions Based on the PIN Questionaire (Part 1 and 3)

Number of Participants Reporting Pain, Using Perception of Injection (PIN) Questionnaire (Part 1 and 3)

Number of Participants With Worst Case Urinalysis at Post-baseline Compared With Baseline

Score Recorded for Acceptance of ISRs, Using Perception of Injection (PIN) Questionnaire (Part 1 and 3)

Score Reported for Post-injection Pain Assessment Using Numeric Rating Scale (NRS) Following VH3810109 SC Administration (Part 1 and 3)

Scores Reported for Post-injection Pain Assessment Using Numeric Rating Scale (NRS) Following VH3810109 IV Administration (Part 2)

The Overall Duration of ISRs, Expressed in Days

Time of Maximum Observed Concentration (Tmax) of VH3810109